Published in final edited form as:

Front Biol (Beijing). 2013 February 1; 8(1): 60–77. doi:10.1007/s11515-012-1196-0.

Progress in *Brucella* vaccine development

Xinghong YANG[✉], Jerod A. SKYBERG, Ling CAO, Beata CLAPP, Theresa THORNBURG, and David W. PASCUAL

Department of Immunology & Infectious Diseases, Montana State University, Bozeman, MT 59717-3610, USA

Abstract

Brucella spp. are zoonotic, facultative intracellular pathogens, which cause animal and human disease. Animal disease results in abortion of fetuses; in humans, it manifests flu-like symptoms with an undulant fever, with osteoarthritis as a common complication of infection. Antibiotic regimens for human brucellosis patients may last several months and are not always completely effective. While there are no vaccines for humans, several licensed live *Brucella* vaccines are available for use in livestock. The performance of these animal vaccines is dependent upon the host species, dose, and route of immunization. Newly engineered live vaccines, lacking well-defined virulence factors, retain low residual virulence, are highly protective, and may someday replace currently used animal vaccines. These also have possible human applications. Moreover, due to their enhanced safety and efficacy in animal models, subunit vaccines for brucellosis show great promise for their application in livestock and humans. This review summarizes the progress of brucellosis vaccine development and presents an overview of candidate vaccines.

Keywords

Brucella; brucellosis; zoonosis; livestock vaccines

Introduction

Brucellosis is a zoonotic disease caused by the bacteria of the genus *Brucella* (Bercovich, 2000). Brucellosis rarely results in human death, but it can pose a significant economic loss to owners of domesticated animals due to loss of progeny, reduced milk yield, and infertility. In animals, brucellosis causes epididymitis in males and abortion, placentitis, and infertility in pregnant livestock (Xavier et al., 2009; Silva et al., 2011b). In humans, brucellosis causes acute inflammation and manifests many symptoms of a flu-like infection, including undulating fever, sweats, headaches, back pains, and physical weakness. In some patients, symptoms of acute brucellosis can endure over one year and eventually result in chronic persistence (Castaño and Solera, 2009). Symptoms of chronic brucellosis include recurrent fevers, joint pain, fatigue, and complications of sacroiliitis, peripheral arthritis, spondylitis, osteomyelitis, and bursitis (Pourbagher et al., 2006).

The genus of *Brucella* is composed of at least ten species (spp.): *B. abortus*, *B. melitensis*, *B. suis*, *B. ovis*, *B. canis*, *B. neotomae*, *B. microti*, *B. inopinata*, *B. pinnipedialis*, and *B. ceti* (Haag et al., 2010). However, two additional species have been identified in nonhuman primates (Schlabritz-Loutsevitch et al., 2009) and foxes (Hofer et al., 2011), implicating further diversity of *Brucella*. The classification of *Brucella* spp. is based largely on the

preferred hosts (origin of identification), as *Brucella* spp. show >94% DNA sequence identity (Chain et al., 2005; Halling et al., 2005). The *B. abortus*, *B. melitensis*, and *B. suis* cause most of the animal and human disease (Corbel, 1997). *B. abortus* is the most widespread (Corbel, 1997), causing abortion in cattle (*Bos* spp.) and chronic infection in humans (Moriyón et al., 2004; Pappas et al., 2005). *B. melitensis* is predominantly a disease of goats (*Capra hircus*) and sheep (*Ovis aries*), but can infect cattle as well (Zowghi and Ebadi, 1985; Buyukcangaz and Sen, 2007), causing placentitis. It is considered the most pathogenic species to humans (Corbel, 1997; Contreras-Rodriguez et al., 2003; Eschenbrenner et al., 2006), at least by the median infective dose by aerosol exposure (Teske et al., 2011), although *B. abortus* appears to cause equally severe disease (Atluri et al., 2011). *B. suis* infects a broad range of animals, including swine (*Sus* spp.), reindeer (*Rangifer tarandus*), caribou (*Rangifer tarandus*), hares (*Lepus* spp.), various murine species (*Mus* spp.), and occasionally cattle and dogs (*Canis* spp.), and is the most diverse in its genome sequence (Moreno and Moriyón, 2001). Although each species has a relative host preference, cross-species infections occur frequently. *B. canis*, a species mostly limited to infecting dogs, is also infectious in cattle (Li, 1988), as *B. melitensis* is in swine (Borts et al., 1946).

Today, approximately half a million new human cases occur each year worldwide (Franco et al., 2007). However, the incidence of disease is believed to be under diagnosed, thus under reported (Abu Shaqra, 2000; Diyu, 2009). In fact, for each case reported, as many as 26 cases are believed to be undiagnosed (Wise, 1980). The primary mode of exposure is the consumption of unpasteurized milk products, while occupational exposure is secondary (Atluri et al., 2011).

Brucellosis will continue to remain an important public health concern as long as natural reservoirs exist. Although live vaccines are available for livestock, their immunization programs must be maintained to limit human infection. Vaccination of uninfected animals and culling of the infected animals have been successfully used to eradicate brucellosis from most of the USA (Ebel et al., 2008; Treanor et al., 2010); however, this approach cannot be used in countries that are unable to provide restitution of the disposed livestock or removal of infected animals because of cultural beliefs. More problematic is the lack of brucellosis vaccines for humans. Hence, development of better vaccines for livestock and humans could circumvent some of the issues and possibly eventually limit the natural reservoir. Notwithstanding the complications in livestock, natural reservoirs for *Brucella* spp. also extend into wildlife (Galindo et al., 2010; Olsen, 2010). Because these *Brucella* reservoirs are unlikely to be eliminated from wildlife, the infection chain from wildlife to livestock and ultimately to humans will remain (Fig. 1). Thus, emphasis on the development of efficacious vaccines for livestock and humans is paramount. Moreover, conventional antibiotic regimens are still not a guarantee for elimination of brucellae from the host, and a relapse rate of 5%–10% is still observed in patients (Hall, 1990; Memish et al., 2000). Finally, *Brucella* was previously used as a bioweapon in World War II (Pappas et al., 2006a), and because of its ease of propagation, it can still today be readily disseminated as an aerosol, causing alarm for its illegitimate use (Valderas and Barrow, 2008; Audic et al., 2009). Given these problems associated with containing and treating this disease, significant efforts are warranted to develop better brucellosis vaccines and treatment regimens.

Brucella has devised multiple mechanisms to evade immune detection. Typically, Gram-negative bacteria lipopolysaccharide (LPS) induces strong proinflammatory responses via the interaction by host pattern recognition receptors, specifically, the toll-like receptor 4 (TLR-4) enabling host recognition (Bäckhed et al., 2003). Yet, *Brucella* LPS does not trigger such inflammatory responses (Haag et al., 2010), thus, avoiding host detection, which is attributed to their side-chain acylation of the LPS molecule that normally dictates

the strength of the TLR4-mediated response (Dueñas et al., 2004). Furthermore, their LPS makes the brucellae highly resistant to cationic bactericidal peptides (Martínez de Tejada et al., 1995), thus, enhancing their survival. To further enhance their survival following infection, brucellae inactivate host defenses by impairing the macrophage response to IFN- γ (Barrionuevo et al., 2011), a key mediator of the innate and adaptive immunity produced during *Brucella* infection (Zhan and Cheers, 1993). To ensure their survival, intracellular brucellae do not induce cell death in macrophages (Barquero-Calvo et al., 2007), and they do not induce apoptotic death in respiratory epithelial cells (Ferrero et al., 2009). To enhance their defense, brucellae can modify their outer membrane by installing phosphatidylcholine to avoid fusion with lysosome (Conde-Alvarez et al., 2006). *Brucella* synthesizes cyclic β -1,2-glucans that interact with the lipid rafts contained in the host cell membrane to prevent fusion between phagosome and lysosome and to successfully survive and replicate intracellularly (Arellano-Reynoso et al., 2005). These studies show how efficient *Brucella* is at infecting the host and is able to survive phagocytosis. In fact, in some estimates, *B. melitensis* infection is highly efficient, the median infectious dose is 1840 colony forming units (CFUs) subcutaneously for the mouse; the median infectious dose by aerosol route is 1924 CFUs for macaques; and the median infectious dose by aerosol is 1885 CFUs for human (Teske et al., 2011).

The development of safe and effective vaccines against both animal and human disease will constitute an important step in curbing brucellosis. Much progress has been made in brucellosis vaccine research, especially during the past decade, expedited by molecular techniques successful sequencing of *Brucella* spp. genomes, and the utilization of the small-rodent animal model. As such, mice can be used as a tool to screen brucellosis vaccines. Experiments with the natural hosts are more appropriate, but often these are problematic due to longer periods of time to perform, special containment facilities, and high costs. Laboratory animal models, particularly the mouse, have the advantage to allow preliminary testing to determine the initial efficacy of vaccines against *Brucella* spp. (Smither et al., 2009). In addition, a number of different mouse strains can readily be infected by *B. abortus* (Silva et al., 2011a). Many symptoms of brucellosis mimic symptoms of large animals, including abortion (Kim et al., 2005), placental infection and lesion, and they also mimic symptoms of humans, including acute and chronic diseases. Mouse models are also able to mimic modes of infection that cause large animal or human *Brucella* infections, as evidenced by oral inhalational routes. However, there are several differences between brucellosis in mice and large animal or human disease: (1) Mice are often infected by the intraperitoneal route, while large animal and human are via the mucosal penetration; (2) brucellosis in mice does not cause fever, while human brucellosis is frequently associated with undulant fever (Silva et al., 2011a); (3) human brucellosis has a deleterious effect on the spleen, liver, heart, bones, and brain (Young, 1989), but brucellosis in mice is mostly limited to brucellae persistence in the spleen and liver (Dornand et al., 2004). Thus, these differences are needed to be considered when adapting results from rodent studies to large animals, and outcomes may differ in these large animals. Nonetheless, understanding basic mechanisms of pathogenesis and identification of a number of virulence factors have been revealed by such evaluations in mice. Moreover, mice can be more readily genetically manipulated to help understand correlates of immune protection and how the host responds to *Brucella* virulence factors. While perhaps only identifying fewer protective antigens in mice, progress can still be made in *Brucella* vaccine development. Thus, this review will summarize the significant achievements in *Brucella* vaccine research and development in both laboratory animals and the large animals.

Live vaccines

Live *B. abortus* vaccine strain 19

The live vaccine *B. abortus* strain 19 (S19) is a spontaneously attenuated mutant discovered in 1923 (Graves, 1943), and attributed to a deletion of 702 bp encompassing the erythritol catabolic genes, manifesting a phenotypic sensitivity to erythritol (Sangari and Agüero, 1994; Sangari et al., 1994). S19 had been used worldwide to prevent brucellosis in cattle for more than half a century until the introduction of the rough vaccine strain RB51 in the mid-1990s (Crasta et al., 2008). Although currently not used in the USA, S19 is still being employed in other countries, such as India (Mukherjee et al., 2005) and Argentina (Baldi et al., 2008). Summarized research results by the National Animal Disease Laboratory showed that 65%–75% S19 immunized cattle were completely protected against most kind of exposure. The remaining 25%–35% of the immunized cattle became infected, but many did not show symptoms, such as abortion (Manthei, 1959). Later, other studies showed that S19 provided 70%–91% protection against cattle abortion (Confer et al., 1985; Wyckoff et al., 2005), although the protective efficacy is challenge dose-dependent (Confer et al., 1985) (Table 1). S19 is also effective in protecting cattle against wild-type (wt) *B. abortus* infections (Cardena et al., 2009). A major drawback of S19 is that it maintains a smooth phenotype due to its intact extracellular O-antigen LPS layer. Since the smooth phenotype induces anti-LPS antibodies, it is difficult to distinguish between cattle naturally infected from those immunized. Since the card test bases positive reactivity on the presence of these anti-LPS antibodies, current vaccination programs in the USA and other countries rely on cattle being immunized with the rough RB51 vaccine because vaccinated animals lack these anti-LPS antibodies. Another problem with S19 is it can cause abortion if given to cows during pregnancy (Smith and Ficht, 1990), and it is fully virulent for humans (Spink et al., 1962). Subcutaneous immunization with S19 in pregnant cattle can result in a 3.2% abortion rate (Beckett and MacDiarmid, 1985), and intravenous immunization of pregnant cows can lead to 100% abortion (Mingle et al., 1941; Taylor and McDiarmid, 1949). To dampen its virulence, but retain its immunogenicity, some studies have focused on modifying S19 (Robertson et al., 1996; Arenas-Gamboa et al., 2009c; Briones et al., 2001). One promising candidate shows a *cgs* (encoding cyclic α -1,2-glucan synthetase) mutant nullifies the host immune response against LPS, while successfully retaining protective efficacy against the wt strain *B. abortus* 2308 (Briones et al., 2001). However, studies with these vaccines await further testing in large animals.

B. abortus can also infect American bison (*Bison bison*) and elk (*Cervus elaphus*) (Scurlock and Edwards, 2010), which serve as wildlife reservoirs for the disease in the Greater Yellowstone Area, USA (Thorne, 1997; Cheville et al., 1998). Subcutaneous or intramuscular vaccination with S19 results in 58% abortion rate in pregnant bison (Davis et al., 1991). S19 is poorly immunogenic in elk (Olsen et al., 2006), but partially protective in red deer (*Cervus elaphus*), a related species of elk, when S19 is microencapsulated (Arenas-Gamboa et al., 2009a). Of note is the microencapsulated S19 is only protective in the spleen by reducing the splenic bacterial load but not the liver and the lung since both organs show no difference from the unvaccinated control in bacterial CFUs. This difference in splenic efficacy between elk and red deer might be due to differences in immunization regimen, since the red deer were orally vaccinated with microencapsulated S19, while the elk were immunized parenterally with S19. Alginate (a naturally occurring polymer combined with a protein of *Fasciola hepatica* vitelline protein B), the main component of the capsule, may display an adjuvant role in enhancing the S19 immunity to red deer. While not eliminating the possibility of differences attributed to species, future studies will be needed to discern whether microencapsulated S19 is effective in protecting elk.

Live *B. abortus* vaccine strain RB51

In 1996, to circumvent the problem incurred by the S19 O-antigen, *B. abortus* RB51 subsequently replaced S19 for vaccinating cattle in the USA against brucellosis (CDC, 1998). This rough mutant strain was derived from smooth wt *B. abortus* 2308. Unlike S19, RB51 does not induce anti-LPS antibody responses, enabling conventional serologic tests for diagnosing brucellosis in cattle, including card, complement fixation, particle concentration fluorescence immunoassay, and tube agglutination tests (Stevens et al., 1994; Stevens and Olsen, 1996). Compared to S19, RB51 is relatively safe as intravenous administration to cattle only causes 25% of heifers to deliver prematurely (Palmer et al., 1996a). Cattle vaccinated with S19 or RB51 display similar lymph node immune responses to *B. abortus* 2308 (Stevens et al., 1995a), and RB51 confers similar protection as S19 to abortion and infection (Cheville et al., 1996b). RB51 can confer full protection in cattle, as none of the RB51-immunized cattle aborted, while 83.3% of the cattle aborted or delivered small, weak calves in the unimmunized control group (Cheville et al., 1993). RB51 induced 100% protection against abortion in cattle when a field strain of *B. abortus* was used, and found to be more effective than S19 (Lord et al., 1998). However, vaccination with RB51 does not protect cattle against *B. suis* infection, as evidenced by infection rates in maternal or fetal tissues (Olsen and Hennager, 2010).

RB51 has been tested in other animals, including water buffalo (*Bubalus bubalis*), sheep, goats, bison, elk, and red deer. RB51 can be safely used in water buffalo (Diptee et al., 2006), but it is not protective against natural *Brucella* infections, as evidenced by the percentage of vaccinated animals seroconverting was greater than the control group (43% versus 15%), and all isolates were confirmed to be *B. abortus* biovar 1 and not RB51 (Fosgate et al., 2003). RB51 is safe in small ruminants (Roop et al., 1991), but it does not protect sheep against abortion induced by wt *B. melitensis* (el Idrissi et al., 2001), nor does RB51 confer protection against *B. ovis* in goats (Jiménez de Bagüés et al., 1995; Herrera et al., 2011). The safety data for RB51 in bison are ambiguous. One study found RB51 causes both abortion (25%) and tissue infection, with the latter leading to placentitis and endometritis (Palmer et al., 1996b). However, another study found RB51 is safe in bison since subcutaneous vaccination did not cause prolonged bacterial colonization of tissues in both calves and adults nor did it induce abortions following vaccination of pregnant bison (Elzer et al., 1998). Efficacy data are also conflicting. One study has found the incidence of abortion due to *B. abortus* challenge is significantly reduced in bison vaccinated with RB51 (1.2×10^{10} – 6.1×10^{10} CFUs) when compared to unvaccinated controls (15% versus 62%) following conjunctival challenge with 3×10^7 CFUs 2308 (Olsen et al., 2003). Furthermore, revaccination of bison with RB51 did not cause abortion, but RB51 was recovered from tissue samples in 16.7% pregnant bison (Olsen and Holland, 2003). In a separate study, RB51 showed little efficacy in adult and calf bison despite repeated subcutaneous vaccinations with 1×10^7 – 1×10^9 CFUs given as a primary immunization and boosted with 1×10^9 CFUs followed by a conjunctival challenge with 1×10^7 CFUs 2308 (Davis and Elzer, 2002). Surprisingly, RB51 was found to be pathogenic to elk since this vaccine induced a 71% abortion rate (Kreeger et al., 2000). Elk that did not abort and were challenged with wt *B. abortus* 2308 produced fetuses that possessed both RB51 and 2308 (Kreeger et al., 2000, 2002). Testing alternative methods to vaccinate, the closely related red deer (*Cervus elaphus elaphus*) has been used as a model for the Rocky Mountain elk (*Cervus elaphus nelsoni*). Red deer vaccinated with microencapsulated RB51 by either the oral or subcutaneous route, showed a significant reduction in splenic colonization (Arenas-Gamboa et al., 2009b).

Two major hindrances are associated with RB51. One is RB51 that is infectious to humans and can cause human brucellosis (Ashford et al., 2004); the other is it is resistant to rifampin (Schurig et al., 1991; Adone et al., 2005), one of the most potent and effective antibiotics for treating brucellosis (Eker et al., 2011; Gulsun et al., 2011).

Attenuated *B. abortus* mutants as vaccine candidates

To develop better performing vaccines, significant efforts have focused on defining the relevant *Brucella* virulence genes. Mutants of the purine biosynthesis pathway genes *purL*, *purD*, and *purE* remained viable in mice 12 weeks after infection (Alcantara et al., 2004), suggesting these were insufficient to attenuate *Brucella*. In contrast, the lipid A fatty acid-transporting gene *bacA* mutant (Walker et al., 2000; Ferguson et al., 2004), the ferrochelatase *hemH* mutant (Almirón et al., 2001), and the type IV secretion *virB* mutant (den Hartigh et al., 2004) were highly attenuated phenotypes, but their protective efficacies remain to be analyzed. Deletion of the phosphoglycerate kinase encoding gene (*pgk*) from wt strain *B. abortus* 2308 resulted in dramatic attenuation. Although Δpgk *B. abortus* induced protection as S19 in interferon regulatory factor-1-deficient mice, which have defects in Th1-type CD8⁺, NK, and $\gamma\delta$ T cell development, and are highly susceptible to brucellosis (Rajashekara et al., 2005). In BALB/c and C57BL/6 mice, Δpgk *B. abortus* was as protective as S19 and RB51 vaccines (Trant et al., 2010). Mutants in the phosphoglucosyltransferase (*pgm*) gene (responsible for isomerizing glucose-6-phosphate to glucose-1-phosphate) or high-affinity zinc uptake system (*znuA*) gene from wt 2308, conferred equivalent protection to S19 (Ugalde et al., 2003; Yang et al., 2006). Δpgm *B. abortus* did not induce a detectable antibody response against O-antigen (Ugalde et al., 2003); therefore, similar to RB51, Δpgm *B. abortus*-infected animals can be distinguished from animals infected with wt brucellae.

Live *B. melitensis* vaccine strain Rev-1

The live vaccine strain Rev-1 was originally derived from wt *B. melitensis* 6056 in 1957 by sequential passage on streptomycin-containing media until streptomycin-resistant clones developed (Elberg and Faunce, 1957). Rev-1 vaccine is innocuous when administered to rams (Muñoz et al., 2008). Rev-1 immunization of goats induces strong immunity that can be maintained for over 2 years (Alton, 1966; Entessar et al., 1967) without side effects, such as prolonged interference with serological tests or shedding (Alton, 1966). Rev-1 has also been found to be protective against natural infections in goats for at least 4.5 years after vaccination, including full protection against abortion versus 45% abortion rate in unvaccinated controls, and 92% versus 16% protection against tissue infection (positive mammary gland, uterus or both) for vaccinated ewes relative to controls (Alton, 1968). On a large scale, Rev-1 was found to be fairly effective in preventing goat and sheep from natural *Brucella* infections. In 2004, Tajikistan adopted a Rev-1 immunization program in small ruminants with 13006 animals. Five years later, the seroprevalence dropped by 80%, but for those districts where no vaccinations were carried out, no change in seroprevalence was observed (Ward et al., 2011). After sheep and goat brucellosis eradication program was implemented in 1999 in Portugal involving 2.4 million animals, the serological positive rate dropped from 2.8% to 0.3% and the serologically positive herds dropped from 8.4% to 1.2% (SCOFAH, 2011).

However, Rev-1 was not found to be safe for pregnant goats. Rev-1 could be isolated in vaginal discharge from ewes, regardless of subcutaneous or conjunctival route of immunization (Jiménez de Bagüés et al., 1989). Rev-1 vaccination of lactating goats demonstrated occasional excretion of brucellae into the milk (Banai, 2002). Further, Rev-1 is virulent to humans (Blasco and Díaz, 1993), and in fact, is more virulent than S19 (Spink et al., 1962). Another drawback rooted in Rev-1 is that immunization can stimulate strong anti-O antigen antibody titers interfering with the serological diagnosis to distinguish between vaccinated animals and natural infection by both *B. melitensis* and *B. ovis* (Fensterbank et al., 1982; Marín et al., 1999). Rev-1 is also subject to varying its morphological and immunological properties (Bosserey, 1991), which can impact its efficacy.

To assess its ability to be cross-protective, Rev-1 was further evaluated for its efficacy against wt *B. abortus*. The results showed Rev-1 being more protective in cows than S19 at protecting against abortion using a challenge dose of 8×10^6 CFUs with wt *B. abortus* 2308 (90% versus 80% in normal parturition) or a high challenge dose of 1×10^9 CFUs with 2308 (40% versus 0% in normal parturition) (García-Carrillo, 1980). However, a recent study isolated Rev-1 from the aborted cattle fetuses subsequent exposure of cattle to Rev-1-immunized ewes, implicating Rev-1's virulence to cows (Pishva and Salehi, 2008). Later, it was found that Rev-1 is able to enter the sheep blood at 1 day after immunization, and persist in blood over 60 days. The persistent bacteremia may account for its transmission capability among animals (Kojouri and Gholami, 2009). Rev-1 also seems to be safe in camels since immunized animals did not abort, and no Rev-1 was recovered from udder secretion samples collected from all vaccinated lactating camels (Radwan et al., 1995).

Live *B. melitensis* mutant vaccine candidates

To develop live vaccines against *B. melitensis* with superior performance to Rev-1, efforts have focused on the deletion of various virulence genes. However, these studies have achieved varied success. Since Rev-1 carries a smooth LPS with an O-antigen that evokes antibodies interfering in serodiagnosis in eradication campaigns, rough *Brucella* mutants without O-antigen have been proposed as vaccines. In this respect, in an attempt to block the expression of LPS from *B. melitensis*, three mutants, defective in core and O-polysaccharide synthesis, were derived: *wbkF* mutant, *per* mutant, and *wa* mutant, each found to be less effective than Rev-1 in sheep. The *wbkF* mutant, the best candidate among the three mutants, still exhibited 38% abortion rate in vaccinated ewes, while Rev-1 vaccinated ewes did not abort after challenge at mid-gestation with virulent wt *B. melitensis* H38. Forty-six percent of *wbkF* mutant-immunized ewes secreted wt *Brucella* in their milk, vaginal swabs, and/or aborted or produced non-viable lambs, while none of the Rev-1 immunized sheep secreted brucellae (Barrio et al., 2009). In a separate study, six other rough *B. melitensis* mutants were developed with different *rpoB* genotypes, and these were able to confer variable levels of protection against wt *B. melitensis* infection in mice via intraperitoneal challenge. Two of these vaccines provided similar efficacy as Rev-1 and were superior to RB51, without inducing O-antigen antibodies (Adone et al., 2005). Another group investigated 14 *B. melitensis* LPS mutants in mice, from which two were able to confer protection equivalent to that obtained with Rev-1 via intraperitoneal challenge, but required a vaccine dose ~1000-fold greater than Rev-1 (González et al., 2008). Recently, our group showed that oral immunization with a $\Delta znuA$ *B. melitensis* 16M mutant conferred better protection than RB51 against intranasal challenge with wt *B. melitensis* 16M, and this observed protection was IFN- γ -dependent (Clapp et al., 2011a). Interestingly, this vaccine is cleared relatively rapidly within 1–2 weeks following oral immunization, suggesting, possibly, oral delivery represents another mode of *Brucella* attenuation. Until tested in livestock, these studies suggest LPS may be an essential protective antigen against *B. melitensis* infections.

In addition to LPS, interruption of other virulence genes in *B. melitensis* has been examined. Immunization of goats with *B. melitensis* high-temperature-requirement A (*htrA*) deletion mutant did not cause abortion, but the vaccine did colonize both the fetus and the nanny (Phillips et al., 1997; Roop et al., 2001). A *purE* *B. melitensis* mutant appeared to be safe in goats, but the protective efficacy remains to be determined (Cheville et al., 1996a). Interruption of *B. melitensis*' major outer membrane protein Omp25 resulted in the attenuation in mice, and the resulting *omp25* mutant provided measurable protection against wt *B. melitensis* challenge (2.29 versus 2.45 log₁₀ units for *omp25* mutant compared to Rev-1); however, this mutant retained residual virulence as mouse spleens contained $>10^3$ CFU by week 8 post-immunization (Edmonds et al., 2002a). Later, *omp25* mutant was

evaluated in goats, and upon immunization of pregnant goats at late gestation, it did not cause abortion (0%), unlike the parental strain *B. melitensis* 16M that induced 100% of the dams to abort (Edmonds et al., 2002b). Prior to breeding, vaccination with *omp25* mutant conferred full protection against abortion following challenge in late gestation with wt strain 16M, a protective efficacy equivalent to Rev-1 (Edmonds et al., 2002b). While the mutant retained virulence for mice, it performed well in a small ruminant model, indicating the murine models may not always predict protection in ruminants.

A *B. melitensis mucR* mutant strain has been found to be highly protective against both intraperitoneal and aerosol challenges with wt *B. melitensis* 16M in BALB/c mice (Arenas-Gamboa et al., 2011). The *mucR* gene is believed to encode for a transcriptional factor involved in exopolysaccharide production for biofilm formation. However, this mutant can persist in mice for as much as 12 weeks post-infection. In contrast, the *vjbR* (encoding quorum sensing regulator) mutation of strain 16M is more readily cleared from mice since a dramatic reduction in splenic CFU burden was observed by 28 days post-infection ($10^{0.5}$ CFUs), and it conferred protection similar to Rev-1 vaccine (Wang et al., 2011). Microencapsulation of a related mutant, *B. melitensis vjbR::Tn5*, in alginate microspheres, resulted in protective efficacy being enhanced by 1.84 $\log_{10}$ units compared to the unencapsulated strain (Arenas-Gamboa et al., 2008). A deletion mutation of *galE* (involved in galactose metabolism) from *B. melitensis* provided similar protective efficacy to Rev-1 in mice, yet its virulence was similar to the parental wt *B. melitensis* 16M strain (Petrovska et al., 1999), making this strain less desirable for application to small ruminants.

Live *B. suis* vaccine strain 2

B. suis strain 2 (S2) is a laboratory adapted strain isolated in 1953 from an aborted sow, which was attenuated by serial passage (Bosseray and Plommet, 1990). Although S2 possesses a smooth phenotype, its virulence is significantly less than wt *B. suis* (Xin, 1986). Since 1958 in China, S2 has been used for oral immunization of livestock by adding the vaccine to the animals' drinking water. S2 has been found to be efficacious by preventing infections in 82.7% of sheep, 82.1% of goats, 75.0% of sows, and 71.4% of cows. As swine are the preferred host for *B. suis*, oral immunization of pigs with S2 once a year for two years lowered the serologic reactivity on farms from 62.8%–75% to 0%–2.4% (Xin, 1986). When evaluated in mice relative to Rev-1 and S19 vaccines, S2 was found to be less virulent than these other vaccines. For short-term immunity, no differences were observed among the three vaccines, but for long-term immunity, immunity induced by S2 declined relative to those vaccinated with Rev-1 and S19 vaccines (Bosseray and Plommet, 1990). S2 was also evaluated for its ability to be delivered by the conjunctival route in rams and ewes for protection against wt *B. ovis*. The results showed that S2 was less protective than Rev-1 in rams (43.7% versus 78.6%, respectively) (Blasco et al., 1993), and in ewe abortion (71%–81% versus 20%–38% for S2 and Rev-1 aborted ewes, respectively) (Verger et al., 1995). This may imply that S2 is not appropriate for usage via conjunctival immunization route, or alternatively, S2 is not effective in protecting infections caused by the species *B. ovis* or *B. melitensis*. Another drawback associated with S2 is that its immunization via drinking water cannot ensure reproducible vaccine doses.

Live *B. suis* mutant vaccine candidates

Mutations of *B. suis* in *aroC* (aromatic amino acid biosynthetic pathway) (Foulongne et al., 2001), *bvfA* (*Brucella* virulence factor A) (Lavigne et al., 2005) or *norD* (nitric oxide reductase) (Loisel-Meyer et al., 2006) resulted in the loss of virulence in mice. However, no efficacy data were provided to compare how well these mutants behaved. Interruption of *eryC* (erythritol metabolism) or *ntrC* (two-component regulatory system) in *B. suis* did not drastically reduce virulence in mice (dropping by only 1.49 $\log_{10}$ units in spleen) (Burkhardt

et al., 2005), implying that these mutants are not sufficiently attenuated for further investigation in pigs.

Subunit *Brucella* vaccines

The advantage of subunit vaccines is they eliminate safety concerns associated with live vaccines, although replicating the immunogenicity of live vaccines is more problematic. Since subunit vaccines avoid utilizing living brucellae, they do not result in animal infection or abortion, and thus are safe for both animals and humans. A number of protective antigens for brucellosis have been identified during the past two decades. These subunit vaccines are formulated either as DNA or purified proteins to stimulate immune responses in animals. As protection to *Brucella* in murine models is typically measured as a reduction in splenic colonization in CFUs ($\log_{10}$ units) relevant to non-vaccinated but challenged controls, various subunit vaccines have been tested. These include: lumazine synthase (Velikovskiy et al., 2002), Bp26 and trigger factor together (Yang et al., 2005), InfC (Cespedes et al., 2000), L7/L12 (Kurar and Splitter, 1997), Omp16 and Omp19 (Pasquevich et al., 2009), Omp25 (Commander et al., 2007), Omp28 (Kaushik et al., 2010), Omp31 (Cassataro et al., 2005), P39 (Al-Mariri et al., 2001), S-adenosyl-L-homocysteine hydrolase (Yang et al., 2011), DnaK and SurA (Delpino et al., 2007), and SodC (Muñoz-Montesino et al., 2004) (The immunization dose and route and challenge dose and route are detailed in Table 2). Subunit vaccines have the advantage of being effective for multiple *Brucella* species because of the >94% gene homology among *Brucella* species (Whatmore, 2009). Although significant protection can be achieved by these subunit vaccines, these too have limitations. Each of these vaccines has a limited scope of efficacy of generally <2 $\log_{10}$ units of protection and usually requires several boosts to achieve immunity. This is generally less effective than the control live vaccines with merely one dose, such as RB51, S19, or Rev-1. Thus, their lack of potency remains problematic compared with live vaccines, and their manufacture can be cost prohibitive. Additionally, a majority of these studies were only performed in mice, which is not always an adequate predictor for protection in livestock or humans.

A few pilot studies were initiated to assess whether subunit vaccines are capable of protecting livestock. The use of *B. ovis* outer membrane proteins entrapped in poly(ϵ -caprolactone) microparticles resulted in nearly equivalent protection in rams (46.2% uninfected) as Rev-1 (42.9% uninfected) (Da Costa Martins et al., 2010). Using *B. abortus* soluble antigens combined with the adjuvant of dimethyldioctadecyl ammonium bromide to immunize steers, both humoral and cell-mediated immune responses were elicited (Dzata et al., 1991). Bison immunized intramuscularly with Bp26 and TF DNA vaccines produced enhanced antibody, proliferative T cell, and IFN- γ responses, indicating elicited cellular immune responses (Clapp et al., 2011b). Future studies are needed to assess the efficacy of this approach in livestock.

Heterologously expressed *Brucella* vaccines

An alternative approach for delivering subunit vaccines is to use live vaccine vectors heterologously expressing *Brucella* protective antigens. This is an effective approach in delivering various antigens (Ascón et al., 2005; Yang et al., 2007). Many of these attenuated vaccine vectors are licensed for use in humans (Osorio et al., 2009; Keller et al., 2010) and have the advantage of being safe. As an example, the attenuated *Salmonella enterica* serovar Typhimurium was used to express *Brucella* fusion protein between L7/L12 and lumazine synthase. It was found that the recombinant fusion vaccine was more protective than the individual recombinant proteins against wt *B. abortus* challenge (1.32–1.58 versus 0.95–1.11 $\log_{10}$ units) (Zhao et al., 2009). However, when compared with *Brucella* live vaccine 104M (1.91 $\log_{10}$ units), the *Salmonella*-based vaccine was still less protective. *B. abortus*

protective antigen, BCSP31 (Pugh et al., 1990), was expressed in attenuated *S. choleraesuis* strain χ 781. Oral immunization of this live vaccine elicited immune responses in both mice and swine (Stabel et al., 1990, 1991; Stabel et al., 1993); however, its protective efficacy was not evaluated. *B. abortus* L7/L12 expressed in *Lactococcus lactis* induced a strong copro-IgA titer, but yielded only 0.5 log₁₀ units of protection in mice and was less effective than S19 (1.3 log₁₀ units) (Pontes et al., 2003).

In some recent studies, RB51 has been adapted as a live vaccine vector for delivering homologous antigens to enhance its anti-*Brucella* immunity. RB51 expressing *sodC* conferred 1.9 log₁₀ units protection relative to the 1.0 log₁₀ unit conferred by RB51 (Vemulapalli et al., 2004). By co-overexpressing *sodC* and *wboA* in RB51, it produced a protective vaccine conferring 3.5 log₁₀ units of protection against wt *B. suis* 1330 challenge (Rajasekaran et al., 2011). *wboA* was expressed in O-antigen deficient *B. melitensis* strain WRRP1, and the recombinant strain conferred robust protection against *B. melitensis* 16M challenge (3.2–4.2 log₁₀ units) in mice (Bandara et al., 2009).

Viral vectors have also been tested for expressing *Brucella* antigens. L7/L12 was expressed in vaccinia virus, but failed to evoke protection against wt *B. abortus* challenge, despite inducing anti-L7/L12 immune responses (Baloglu et al., 2005). *B. abortus* translation initiation factor 3 (IF3) and *sodC* were expressed in replication-deficient Semliki Forest virus, and significant resistance against challenge of wt *B. abortus* 2308 was achieved (1.1 and 1.5 log₁₀ units, respectively); however, this level of protection was less than that of RB51 (1.9 log₁₀ units) (Cabrera et al., 2009; Oñate et al., 2005).

Future directions of *Brucella* vaccine development

Alternative marker genes for developing next generation live *Brucella* vaccines

Live *Brucella* vaccines will still need to be researched and improved regarding both safety and protective efficacy despite the availability of current commercial animal vaccines. *Brucella* LPS is very immunogenic, and it is used to differentiate immunized cattle from those naturally infected. While the RB51 vaccine is convenient, it has still proven to be less than ideal, given the susceptibility of vaccinated cattle to brucellosis in the Greater Yellowstone Area in the USA (Olsen et al., 2009; Van Campen and Rhyhan, 2010). This reduced efficacy may be in part attributed to the lack of LPS by RB51, and LPS may in fact be important for protection. *B. melitensis* LPS is a protective antigen in mice, conferring 2.0 log₁₀ units (Bhattacharjee et al., 2006). *B. abortus* LPS also is an essential component of an effective subcellular vaccine, conferring protective immunity in mice (Winter et al., 1988). Comparison of S19 and RB51 efficacy in mice reveals that S19 is more efficacious against wt 2308 challenge than RB51 despite a 100-fold greater RB51 was used than S19 (Stevens et al., 1995b). A recent study shows that a single S19 immunization dose conferred sterile protection against wt *B. abortus* 544 challenge in water buffalo in all the tissues examined, unlike RB51 provided only 80% protection in the retropharyngeal lymph nodes, despite animals being immunized twice (Caporale et al., 2010). Without LPS, in many circumstances, the rough *Brucella* mutants are not protective. Therefore, it may be time to re-examine the notion that a live *Brucella* vaccine should include LPS and use other brucellae markers or genes to differentiate infected from vaccinated animals (DIVA). Currently, multiple candidates can be used as marker (DIVA) genes, including bp26, P39, and green/red fluorescent protein (GFP/RFP). Bp26 is a potent immunogen (Cloekaert et al., 1996); however, its deletion does not lower the protective capacity of S19 in either mice (Boschioli et al., 1997) or pregnant heifers (Fiorentino et al., 2008) despite the abatement of anti-Bp26 titers. Similarly, the immunodominant protein P39, whose deletion from S19 did not affect the protective efficacy in mice (Tibor et al., 1998), may also serve as a marker gene. Heterologous proteins expressed in *Brucella* vaccines, e.g. GFP or RFP, can also be

used as marker genes to distinguish vaccinated mice from those naturally infected with wt *Brucella* (Chacón-Díaz et al., 2011). By selecting alternative marker genes, either by deleting immunogenic proteins or expression of heterologous antigens, the protective antigen LPS can be maintained, imparting the live vaccines with the ability to stimulate robust protection.

Construction of Th1 cell-biased live *Brucella* vaccine

Two indices are important for evaluating a live *Brucella* vaccine in the laboratory murine model: residual virulence and protection against both infection and abortion subsequent to virulent *Brucella* challenge. Any residual virulence requires examining the vaccine's ability to infect and how long it can persist in the host's tissues and organs. Previous work with *Salmonella*-based vaccines suggests some level of persistence is required for protection (O'Callaghan et al., 1988). Obviously this residual virulence cannot be too great to cause disease; yet this residual virulence cannot be too low being unable to stimulate protective immunity. An appropriate residual virulence carried by the live vaccine would allow it to elicit potent protective immunity while not causing disease or abortion. This has been demonstrated in our laboratory when two virulence factors were deleted from *B. abortus* 2308, creating the double mutant, $\Delta znuA\Delta purE$ *B. abortus* strain, which was found to be highly attenuated in mice, and no brucellae could be detected in spleens after 8 weeks post-infection (Yang et al., 2010). In contrast, its parent strain $\Delta purE$ or $\Delta znuA$ *B. abortus* could be detected at 8 and 12 weeks post-infection, respectively (Alcantara et al., 2004; Yang et al., 2006). This suggests $\Delta znuA\Delta purE$ *B. abortus* is safer than either $\Delta znuA$ or $\Delta purE$ *B. abortus* strains. The $\Delta znuA\Delta purE$ *B. abortus* strain required two doses for immunization to elicit optimal protection efficacy (0.79 log₁₀ units), while such an efficacy could be achieved by a single dose of the $\Delta znuA$ *B. abortus* strain (Yang et al., 2010). This indicates that the more attenuated the mutant is, the less protective it will be. Thus, this shows the importance of generating a mutant strain with minimal residual virulence that retains maximal immunogenicity.

Since the majority of the *Brucella* live vaccine selection is primarily based upon mouse models, and the results achieved from mice do not always reflect results obtained in livestock, indices other than the virulence and protection could be useful. A cytokine profile may be such an index since previous studies have shown that Th1 cell-dominant responses are required for protection against *Brucella* infection (Arenas-Gamboa et al., 2008; Rafiei et al., 2006). The Δpgm *B. abortus* yielded a cytokine profile typical of a Th1-type response with a high-level induction of IFN- γ and the absence of IL-4 secretion (Ugalde et al., 2003). As anticipated, it induced protection (~2.0 log₁₀ units) against wt *B. abortus* 2308 in mice, compatible to that conferred by S19. Oral immunization with the $\Delta znuA$ *B. melitensis* resulted in undetectable CFUs in spleens, Peyer's patches (PPs), and mesenteric lymph nodes (MLNs) by two weeks following immunization, unlike mice orally vaccinated with a similar dose of RB51 or S19 that contained elevated CFUs in these same lymphoid tissues (Clapp et al., 2011a). This suggests that $\Delta znuA$ *B. melitensis* is considerably less virulent than the livestock vaccines of RB51 and S19, indicating the $\Delta znuA$ *B. melitensis* is potentially safe. Although the $\Delta znuA$ *B. melitensis* vaccine was cleared relatively rapidly from the host, it stimulated potent immunity in which 83% of the mice nasally challenged with wt *B. melitensis* showed no brucellae in their spleens (Clapp et al., 2011a). This protective effect was considerably subdued in IFN- $\gamma^{-/-}$ mice, although significant protection (1.85 log₁₀ units) was still observed. To evaluate the cytokines induced by $\Delta znuA$ *B. melitensis*, lymphocytes were restimulated with heat-killed RB51 and found to produce elevated levels of IFN- γ , as did RB51-vaccinated mice prior to and after pulmonary challenge. Thus, the $\Delta znuA$ *B. melitensis* data suggest short-term infection is sufficient to stimulate enduring IFN- γ responses, which could be attributed to the expressed LPS, and

RB51-vaccinated mice's duration of infection may be important since RB51 lacks LPS. Alternatively, RB51 stimulates different attributes of the immune system. Nonetheless, short-term infection with $\Delta znuA$ *B. melitensis* achieved robust protection against wt *B. melitensis* challenge, as opposed to RB51-vaccinated mice that showed only 42% with sterile immunity and variable levels of protection or no protection (Clapp et al., 2011a). The differences in protection observed between $\Delta znuA$ *B. melitensis* and RB51 may, in part, be due to the co-stimulation of IL-17. Although neutralization of IL-17 in unvaccinated mice did not show enhanced *B. melitensis* colonization, IFN- $\gamma^{-/-}$ mice required IL-17 for protection. Moreover, while $\Delta znuA$ *B. melitensis*-vaccinated wt mice showed no dependence upon IL-17 for protection, IL-17 was required for $\Delta znuA$ *B. melitensis*-mediated protection in IFN- $\gamma^{-/-}$ mice. IFN- γ competent and deficient mice vaccinated with RB51 displayed higher bacterial burdens when IL-17 was neutralized (Clapp et al., 2011a). Thus, this evidence suggests some vaccines may have a co-reliance upon alternative cell-mediated immune mechanisms.

In a similar vein, subunit vaccines that promote cell-mediated immunity generally show enhanced protective capacities. BCSP31, SodC, and L7/L12 (Yu et al., 2007), Omp16 or Omp19 (Pasquevich et al., 2009), and Omp25 (Commander et al., 2007) have been shown to stimulate antigen-specific IgG responses with IgG2a > IgG1 titers, indicating a Th1-type biased immune response. Due to the effectiveness of Th1-type immunity in predicting the vaccine's performance in the murine model, Th1 cell immunity can be used as a parameter to predict potential *Brucella* vaccine's efficacy in the preliminary screenings of candidate vaccines.

Human and other large animal brucellosis vaccines

The lack of a human brucellosis vaccine remains problematic due to the risk of *Brucella* as a possible bio-terrorist agent, and because brucellosis remains a global disease affecting more than 500,000 people annually (Franco et al., 2007). Since *B. melitensis* is the most frequently acquired among all the *Brucella* spp., a live human *Brucella* vaccine based upon *B. melitensis* should be considered. Due to its low virulence and the excellent protective efficacy, $\Delta znuA$ *B. melitensis* makes an excellent candidate (Clapp et al., 2011a). Likewise, another promising candidate for *B. melitensis* is one deleted of *pgm*, and Δpgm *B. abortus* may be a promising candidate for cattle due to its capability of not eliciting anti-LPS antibody while conferring substantial protection in mice. These vaccines will require further evaluation to learn whether these strains are sufficiently attenuated in primates. If not, *pgm* could be deleted from $\Delta znuA$ *B. melitensis* to generate a double mutant strain, or an additional virulence factor will be deleted from either $\Delta znuA$ *B. melitensis* or Δpgm *B. melitensis* to further strengthen their safety.

Subunit and recombinant human vaccines against *Brucella*, due to their enhanced safety and cross-species protection traits, should also be considered. For subunit vaccines, efforts should be focused on how to optimize the formulation, e.g., selecting the optimal adjuvant. For the live recombinant *Brucella* vaccines, using the licensed human vaccines as vaccine vectors, such as *S. typhi* Ty21a (Levine et al., 1999) or gut commensal bacteria such as *L. lactis* (Shi et al., 2006), may further human brucellosis vaccine development.

Until human vaccines become available, to control human brucellosis, animal vaccination campaigns need to be maintained because human health can benefit tremendously from livestock vaccination campaign (Roth et al., 2003; Jelastopulu et al., 2008). Brucellosis is the most commonly acquired zoonotic disease, and humans become infected upon exposure to infected animals and their products, so preventing infection in animals is of paramount importance to eradicate human brucellosis. Control of brucellosis via mass immunization

campaigns of livestock has proven effective in the USA (Pappas et al., 2006b), Mongolia (Kolar, 1977), China (Xin, 1986), and Greece (Minas et al., 2004). In the USA, because of the massive eradication campaign, human brucellosis cases dropped from 6321 cases in 1947, to 2215 cases in 1973–1982, to 1201 cases in 1983–1992, to 1056 cases in 1993–2002 (Pappas et al., 2006b). From 1971 to 1981, in the Inner Mongolia Autonomous Region of China, sheep and goats were immunized with S2 vaccine. Due to the cessation of *Brucella*-induced abortion in small ruminants, the incidence of brucellosis in humans also significantly dropped, with no new cases occurring since 1983 (Xin, 1986). In contrast, in Mongolia, the country-wide mass-vaccination program of livestock successfully reduced human brucellosis to less than one case per 10000 people per year (Kolar, 1977), but this program was interrupted in the early 1980s due to the termination of WHO and assistance from the former Soviet Union in 1990, and human brucellosis re-emerged (Zinsstag et al., 2005). Vaccination of sheep and goats with Rev-1 for 15 years in Greece decreased their abortions and the incidence of brucellosis in humans. After the vaccination program was stopped in 1994, the prevalence of brucellosis in animals and humans quickly increased in Greece (Minas et al., 2004).

Concluding remarks

Brucellosis remains a global health problem affecting at least a half million people annually (Franco et al., 2007) and potentially as many as 13 million because of misdiagnosis (Wise, 1980). Although brucellosis can be treated with antibiotics, the extended time for treatment impacts compliance, and the lack of vaccines for humans will continue to make this disease a global health threat. This is further complicated by the prevalence of brucellosis in livestock, particularly, in countries lacking the resources to have an effective eradication program. While vaccination of livestock with conventional vaccines could certainly dampen the impact of brucellosis, better livestock vaccines are needed, especially for *B. abortus*, since infections can still occur in vaccinated animals. Thus, continued efforts will be needed to develop more efficacious livestock vaccines and to generate human vaccines. To date, live *Brucella* vaccine candidates show the best promise for livestock, and further testing, including oral formulations (Clapp et al., 2011a) in relevant livestock and wildlife will be needed. While surely live *Brucella* vaccines offer one possibility, such live vaccines would have to be sufficiently mutated, minimizing multiple virulence factors to ensure these are safe and not overly attenuated where it is rapidly cleared. Alternatively, subunit *Brucella* vaccines that can recapitulate aspects of protective immunity would certainly be desirable and may require multiple epitopes (vaccine targets) for optimal efficacy. Thus, much work is needed at multiple fronts to minimize contamination of food products, improve livestock health status, and provide intervention strategies to prevent and treat brucellosis.

Acknowledgments

This work was supported by grants from National Institutes of Health Grant R21 AI-080960, 1R01 AI-093372, P20 RR020185, GM103500, USDA-NIFA grant 2010-34397-21391, US Department of Agriculture Formula Funds, and Montana Agricultural Experiment Station.

References

- Abu Shaqra QM. Epidemiological aspects of brucellosis in Jordan. *Eur J Epidemiol.* 2000; 16(6):581–584. [PubMed: 11049102]
- Adone R, Ciuchini F, Marianelli C, Tarantino M, Pistoia C, Marcon G, Petrucci P, Francia M, Riccardi G, Pasquali P. Protective properties of rifampin-resistant rough mutants of *Brucella melitensis*. *Infect Immun.* 2005; 73(7):4198–4204. [PubMed: 15972510]
- Al-Mariri A, Tibor A, Mertens P, De Bolle X, Michel P, Godefroid J, Walravens K, Letesson JJ. Protection of BALB/c mice against *Brucella abortus* 544 challenge by vaccination with

- bacterioferritin or P39 recombinant proteins with CpG oligodeoxynucleotides as adjuvant. *Infect Immun.* 2001; 69(8):4816–4822. [PubMed: 11447155]
- Alcantara RB, Read RD, Valderas MW, Brown TD, Roop RM 2nd. Intact purine biosynthesis pathways are required for wild-type virulence of *Brucella abortus* 2308 in the BALB/c mouse model. *Infect Immun.* 2004; 72(8):4911–4917. [PubMed: 15271960]
- Almirón M, Martínez M, Sanjuan N, Ugalde RA. Ferrochelatase is present in *Brucella abortus* and is critical for its intracellular survival and virulence. *Infect Immun.* 2001; 69(10):6225–6230. [PubMed: 11553564]
- Alton GG. Duration of the immunity produced in goats by the Rev. 1 *Brucella melitensis* vaccine. *J Comp Pathol.* 1966; 76(3):241–253. [PubMed: 6007463]
- Alton GG. Further studies on the duration of the immunity produced in goats by the Rev. 1 *Brucella melitensis* vaccine. *J Comp Pathol.* 1968; 78(2):173–178. [PubMed: 5648807]
- Arellano-Reynoso B, Lapaque N, Salcedo S, Briones G, Ciocchini AE, Ugalde R, Moreno E, Moriyón I, Gorvel JP. Cyclic β -1,2-glucan is a *Brucella* virulence factor required for intracellular survival. *Nat Immunol.* 2005; 6(6):618–625. [PubMed: 15880113]
- Arenas-Gamboa AM, Ficht TA, Davis DS, Elzer PH, Kahl-McDonagh M, Wong-Gonzalez A, Rice-Ficht AC. Oral vaccination with microencapsulated strain 19 vaccine confers enhanced protection against *Brucella abortus* strain 2308 challenge in red deer (*Cervus elaphus* elaphus). *J Wildl Dis.* 2009a; 45(4):1021–1029. [PubMed: 19901378]
- Arenas-Gamboa AM, Ficht TA, Davis DS, Elzer PH, Wong-Gonzalez A, Rice-Ficht AC. Enhanced immune response of red deer (*Cervus elaphus*) to live rb51 vaccine strain using composite microspheres. *J Wildl Dis.* 2009b; 45(1):165–173. [PubMed: 19204345]
- Arenas-Gamboa AM, Ficht TA, Kahl-McDonagh MM, Gomez G, Rice-Ficht AC. The *Brucella abortus* S19 Δ vjbR live vaccine candidate is safer than S19 and confers protection against wild-type challenge in BALB/c mice when delivered in a sustained-release vehicle. *Infect Immun.* 2009c; 77(2):877–884. [PubMed: 19047401]
- Arenas-Gamboa AM, Ficht TA, Kahl-McDonagh MM, Rice-Ficht AC. Immunization with a single dose of a microencapsulated *Brucella melitensis* mutant enhances protection against wild-type challenge. *Infect Immun.* 2008; 76(6):2448–2455. [PubMed: 18362129]
- Arenas-Gamboa AM, Rice-Ficht AC, Kahl-McDonagh MM, Ficht TA. Protective efficacy and safety of *Brucella melitensis* 16M Δ mucR against intraperitoneal and aerosol challenge in BALB/c mice. *Infect Immun.* 2011; 79(9):3653–3658. [PubMed: 21708998]
- Ascón MA, Ochoa-Repáraz J, Walters N, Pascual DW. Partially assembled K99 fimbriae are required for protection. *Infect Immun.* 2005; 73 (11):7274–7280. [PubMed: 16239523]
- Ashford DA, di Pietra J, Lingappa J, Woods C, Noll H, Neville B, Weyant R, Bragg SL, Spiegel RA, Tappero J, Perkins BA. Adverse events in humans associated with accidental exposure to the livestock brucellosis vaccine RB51. *Vaccine.* 2004; 22(25–26):3435–3439. [PubMed: 15308369]
- Atluri VL, Xavier MN, de Jong MF, den Hartigh AB, Tsolis RE. Interactions of the human pathogenic *Brucella* species with their hosts. *Annu Rev Microbiol.* 2011; 65(1):523–541. [PubMed: 21939378]
- Audic S, Lescot M, Claverie JM, Scholz HC. *Brucella microti*: the genome sequence of an emerging pathogen. *BMC Genomics.* 2009; 10 (1):352. [PubMed: 19653890]
- Bäckhed F, Normark S, Schweda EK, Oscarson S, Richter-Dahlfors A. Structural requirements for TLR4-mediated LPS signalling: a biological role for LPS modifications. *Microbes Infect.* 2003; 5(12):1057–1063. [PubMed: 14554246]
- Baldi PC, Wallach JC, Ferrero MC, Delpino MV, Fossati CA. Occupational infection due to *Brucella abortus* S19 among workers involved in vaccine production in Argentina. *CMI.* 2008; 14:805–807. [PubMed: 18727806]
- Baloglu S, Boyle SM, Vemulapalli R, Sriranganathan N, Schurig GG, Toth TE. Immune responses of mice to vaccinia virus recombinants expressing either *Listeria monocytogenes* partial listeriolysin or *Brucella abortus* ribosomal L7/L12 protein. *Vet Microbiol.* 2005; 109(1–2):11–17. [PubMed: 15941627]

- Banai M. Control of small ruminant brucellosis by use of *Brucella melitensis* Rev.1 vaccine: laboratory aspects and field observations. *Vet Microbiol.* 2002; 90(1–4):497–519. [PubMed: 12414167]
- Bandara AB, Poff-Reichow SA, Nikolich M, Hoover DL, Sriranganathan N, Schurig GG, Dobrea V, Boyle SM. Simultaneous expression of homologous and heterologous antigens in rough, attenuated *Brucella melitensis*. *Microbes Infect.* 2009; 11(3):424–428. [PubMed: 19397881]
- Barquero-Calvo E, Chaves-Olarte E, Weiss DS, Guzmán-Verri C, Chacón-Díaz C, Rucavado A, Moriyón I, Moreno E. *Brucella abortus* uses a stealthy strategy to avoid activation of the innate immune system during the onset of infection. *PLoS ONE.* 2007; 2(7):e631. [PubMed: 17637846]
- Barrio MB, Grilló MJ, Muñoz PM, Jacques I, González D, de Miguel MJ, Marín CM, Barberán M, Letesson JJ, Gorvel JP, Moriyón I, Blasco JM, Zygmunt MS. Rough mutants defective in core and O-polysaccharide synthesis and export induce antibodies reacting in an indirect ELISA with smooth lipopolysaccharide and are less effective than Rev 1 vaccine against *Brucella melitensis* infection of sheep. *Vaccine.* 2009; 27(11):1741–1749. [PubMed: 19186196]
- Barrionuevo P, Delpino MV, Velásquez LN, García Samartino C, Coria LM, Ibañez AE, Rodríguez ME, Cassataro J, Giambartolomei GH. *Brucella abortus* inhibits IFN- γ -induced Fc γ RI expression and Fc γ RI-restricted phagocytosis via toll-like receptor 2 on human monocytes/macrophages. *Microbes Infect.* 2011; 13(3):239–250. [PubMed: 21070860]
- Beckett FW, MacDiarmid SC. The effect of reduced-dose *Brucella abortus* strain 19 vaccination in accredited dairy herds. *Br Vet J.* 1985; 141(5):507–514. [PubMed: 4063777]
- Bercovich Z. The use of skin delayed-type hypersensitivity as an adjunct test to diagnose brucellosis in cattle: a review. *Vet Q.* 2000; 22(3):123–130. [PubMed: 10952440]
- Bhattacharjee AK, Izadjoo MJ, Zollinger WD, Nikolich MP, Hoover DL. Comparison of protective efficacy of subcutaneous versus intranasal immunization of mice with a *Brucella melitensis* lipopolysaccharide subunit vaccine. *Infect Immun.* 2006; 74(10):5820–5825. [PubMed: 16988260]
- Blasco JM, Díaz R. *Brucella melitensis* Rev-1 vaccine as a cause of human brucellosis. *Lancet.* 1993; 342(8874):805. [PubMed: 8103891]
- Blasco JM, Marín C, Jiménez de Bagüés MP, Barberán M. Efficacy of *Brucella suis* strain 2 vaccine against *Brucella ovis* in rams. *Vaccine.* 1993; 11(13):1291–1294. [PubMed: 8296481]
- Borts IH, McNutt SH, Jordan CF. *Brucella melitensis* isolated from swine tissues in Iowa. *J Am Med Assoc.* 1946; 130(14):966–966. [PubMed: 21019101]
- Boschiroli ML, Cravero SL, Arese AI, Campos E, Rossetti OL. Protection against infection in mice vaccinated with a *Brucella abortus* mutant. *Infect Immun.* 1997; 65(2):798–800. [PubMed: 9009345]
- Bosseray N. *Brucella melitensis* Rev. 1 living attenuated vaccine: stability of markers, residual virulence and immunogenicity in mice. *Biologicals.* 1991; 19(4):355–363. [PubMed: 1797046]
- Bosseray N, Plommet M. *Brucella suis* S2, *brucella melitensis* Rev. 1 and *Brucella abortus* S19 living vaccines: residual virulence and immunity induced against three *Brucella* species challenge strains in mice. *Vaccine.* 1990; 8(5):462–468. [PubMed: 2123586]
- Briones G, Iñón de Iannino N, Roset M, Vigliocco A, Paulo PS, Ugalde RA. *Brucella abortus* cyclic beta-1,2-glucan mutants have reduced virulence in mice and are defective in intracellular replication in HeLa cells. *Infect Immun.* 2001; 69(7):4528–4535. [PubMed: 11401996]
- Burkhardt S, Jiménez de Bagüés MP, Liautard JP, Köhler S. Analysis of the behavior of *eryC* mutants of *Brucella suis* attenuated in macrophages. *Infect Immun.* 2005; 73(10):6782–6790. [PubMed: 16177356]
- Buyukcangaz E, Sen A. The first isolation of *Brucella melitensis* from bovine aborted fetus in Turkey. *J Biol Environ Sci.* 2007; 1:139–142.
- Cabrera A, Sáez D, Céspedes S, Andrews E, Oñate A. Vaccination with recombinant Semliki Forest virus particles expressing translation initiation factor 3 of *Brucella abortus* induces protective immunity in BALB/c mice. *Immunobiology.* 2009; 214(6):467–474. [PubMed: 19150742]
- Caporale V, Bonfini B, Di Giannatale E, Di Provvido A, Forcella S, Giovannini A, Tittarelli M, Scacchia M. Efficacy of *Brucella abortus* vaccine strain RB51 compared to the reference vaccine *Brucella abortus* strain 19 in water buffalo. *Vet Ital.* 2010; 46(1):13–19. [PubMed: 20391363]

- Cardena AP, Herrera DM, Zamora JLF, Pina FB, Sanchez BM, Ruiz EJG, Williams JJ, Alvarez FM, Castro RF. Evaluation of vaccination with *Brucella abortus* S19 vaccine in cattle naturally infected with brucellosis in productive systems found in the Mexican Tropic. *Int J Dairy Sci.* 2009; 4(4): 142–151.
- Cassataro J, Estein SM, Pasquevich KA, Velikovsky CA, de la Barrera S, Bowden R, Fossati CA, Giambartolomei GH. Vaccination with the recombinant *Brucella* outer membrane protein 31 or a derived 27-amino-acid synthetic peptide elicits a CD4⁺ T helper 1 response that protects against *Brucella melitensis* infection. *Infect Immun.* 2005; 73(12):8079–8088. [PubMed: 16299302]
- Castaño MJ, Solera J. Chronic brucellosis and persistence of *Brucella melitensis* DNA. *J Clin Microbiol.* 2009; 47(7):2084–2089. [PubMed: 19420176]
- Centers for Disease Control and Prevention (CDC). Human exposure to *Brucella abortus* strain RB51—Kansas, 1997. *MMWR Morb Mortal Wkly Rep.* 1998; 47(9):172–175. [PubMed: 9518281]
- Cespedes S, Andrews E, Folch H, Oñate A. Identification and partial characterisation of a new protective antigen of *Brucella abortus*. *J Med Microbiol.* 2000; 49(2):165–170. [PubMed: 10670567]
- Chacón-Díaz C, Muñoz-Rodríguez M, Barquero-Calvo E, Guzmán-Verri C, Chaves-Olarte E, Grilló MJ, Moreno E. The use of green fluorescent protein as a marker for *Brucella* vaccines. *Vaccine.* 2011; 29(3):577–582. [PubMed: 21056079]
- Chain PS, Comerici DJ, Tolmasky ME, Larimer FW, Malfatti SA, Vergez LM, Aguero F, Land ML, Ugalde RA, Garcia E. Whole-genome analyses of speciation events in pathogenic Brucellae. *Infect Immun.* 2005; 73(12):8353–8361. [PubMed: 16299333]
- Chevillie, NF.; McCullough, DR.; Paulson, LR. Brucellosis in the greater Yellowstone area. Vol National Research Council (U.S.). Board on Agriculture. National Research Council (U.S.). Board on Environmental Studies and Toxicology; Washington DC: National Academy Press; 1998.
- Chevillie NF, Olsen SC, Jensen AE, Stevens MG, Florance AM, Houg HS, Drazek ES, Warren RL, Hadfield TL, Hoover DL. Bacterial persistence and immunity in goats vaccinated with a *purE* deletion mutant or the parental 16M strain of *Brucella melitensis*. *Infect Immun.* 1996a; 64(7): 2431–2439. [PubMed: 8698463]
- Chevillie NF, Olsen SC, Jensen AE, Stevens MG, Palmer MV, Florance AM. Effects of age at vaccination on efficacy of *Brucella abortus* strain RB51 to protect cattle against brucellosis. *Am J Vet Res.* 1996b; 57(8):1153–1156. [PubMed: 8836366]
- Chevillie NF, Stevens MG, Jensen AE, Tatum FM, Halling SM. Immune responses and protection against infection and abortion in cattle experimentally vaccinated with mutant strains of *Brucella abortus*. *Am J Vet Res.* 1993; 54(10):1591–1597. [PubMed: 8250382]
- Clapp B, Skyberg JA, Yang X, Thornburg T, Walters N, Pascual DW. Protective live oral brucellosis vaccines stimulate Th1 and Th17 cell responses. *Infect Immun.* 2011a; 79(10):4165–4174. [PubMed: 21768283]
- Clapp B, Walters N, Thornburg T, Hoyt T, Yang X, Pascual DW. DNA vaccination of bison to brucellar antigens elicits elevated antibody and IFN- γ responses. *J Wildl Dis.* 2011b; 47(3):501–510. [PubMed: 21719815]
- Cloeckaert A, Debbarh HS, Vizcaino N, Saman E, Dubray G, Zygmunt MS. Cloning, nucleotide sequence, and expression of the *Brucella melitensis* bp26 gene coding for a protein immunogenic in infected sheep. *FEMS Microbiol Lett.* 1996; 140(2–3):139–144. [PubMed: 8764475]
- Commander NJ, Spencer SA, Wren BW, MacMillan AP. The identification of two protective DNA vaccines from a panel of five plasmid constructs encoding *Brucella melitensis* 16M genes. *Vaccine.* 2007; 25(1):43–54. [PubMed: 17049676]
- Conde-Alvarez R, Grilló MJ, Salcedo SP, de Miguel MJ, Fugier E, Gorvel JP, Moriyón I, Iriarte M. Synthesis of phosphatidylcholine, a typical eukaryotic phospholipid, is necessary for full virulence of the intracellular bacterial parasite *Brucella abortus*. *Cell Microbiol.* 2006; 8(8):1322–1335. [PubMed: 16882035]
- Confer AW, Hall SM, Faulkner CB, Espe BH, Deyoe BL, Morton RJ, Smith RA. Effects of challenge dose on the clinical and immune responses of cattle vaccinated with reduced doses of *Brucella abortus* strain 19. *Vet Microbiol.* 1985; 10(6):561–575. [PubMed: 3938101]

- Contreras-Rodriguez A, Ramirez-Zavala B, Contreras A, Schurig GG, Sriranganathan N, Lopez-Merino A. Purification and characterization of an immunogenic aminopeptidase of *Brucella melitensis*. *Infect Immun*. 2003; 71(9):5238–5244. [PubMed: 12933870]
- Cook WE, Williams ES, Thorne ET, Kreeger TJ, Stout G, Bardsley K, Edwards H, Schurig G, Colby LA, Enright F. *Brucella abortus* strain RB51 vaccination in elk. I. Efficacy of reduced dosage. *J Wildl Dis*. 2002; 38:18–26. [PubMed: 11838212]
- Corbel MJ. Brucellosis: an overview. *Emerg Infect Dis*. 1997; 3(2):213–221. [PubMed: 9204307]
- Crasta OR, Folkerts O, Fei Z, Mane SP, Evans C, Martino-Catt S, Bricker B, Yu G, Du L, Sobral BW. Genome sequence of *Brucella abortus* vaccine strain S19 compared to virulent strains yields candidate virulence genes. *PLoS ONE*. 2008; 3(5):e2193. [PubMed: 18478107]
- Da Costa Martins R, Irache JM, Blasco JM, Muñoz MP, Marín CM, Jesús Grilló M, Jesús De Miguel M, Barberán M, Gamazo C. Evaluation of particulate acellular vaccines against *Brucella ovis* infection in rams. *Vaccine*. 2010; 28(17):3038–3046. [PubMed: 19887131]
- Davis DS, Elzer PH. *Brucella* vaccines in wildlife. *Vet Microbiol*. 2002; 90(1–4):533–544. [PubMed: 12414169]
- Davis DS, Templeton JW, Ficht TA, Huber JD, Angus RD, Adams LG. *Brucella abortus* in Bison. II. Evaluation of strain 19 vaccination of pregnant cows. *J Wildl Dis*. 1991; 27(2):258–264. [PubMed: 1906114]
- Delpino MV, Estein SM, Fossati CA, Baldi PC, Cassataro J. Vaccination with *Brucella* recombinant DnaK and SurA proteins induces protection against *Brucella abortus* infection in BALB/c mice. *Vaccine*. 2007; 25(37–38):6721–6729. [PubMed: 17686554]
- den Hartigh AB, Sun YH, Sondervan D, Heuvelmans N, Reinders MO, Ficht TA, Tsolis RM. Differential requirements for VirB1 and VirB2 during *Brucella abortus* infection. *Infect Immun*. 2004; 72(9):5143–5149. [PubMed: 15322008]
- Diju IU. Brucellosis—an under-estimated cause of arthralgia & muscular pains in general population. *J Ayub Med Coll Abbottabad*. 2009; 21(2):128–131. [PubMed: 20524489]
- Diptee MD, Adesiyun AA, Asgarali Z, Campbell M, Adone R. Serologic responses, biosafety and clearance of four dosages of *Brucella abortus* strain RB51 in 6–10 months old water buffalo (*Bubalus bubalis*). *Vet Immunol Immunopathol*. 2006; 109(1–2):43–55. [PubMed: 16112746]
- Dornand J, Lafont V, Oliaro J, Terraza A, Castaneda-Roldan E, Liautard JP. Impairment of intramacrophagic *Brucella suis* multiplication by human natural killer cells through a contact-dependent mechanism. *Infect Immun*. 2004; 72(4):2303–2311. [PubMed: 15039355]
- Dueñas AI, Orduña A, Crespo MS, García-Rodríguez C. Interaction of endotoxins with Toll-like receptor 4 correlates with their endotoxic potential and may explain the proinflammatory effect of *Brucella* spp. LPS. *Int Immunol*. 2004; 16(10):1467–1475. [PubMed: 15339879]
- Dzata GK, Confer AW, Wyckoff JH 3rd. The effects of adjuvants on immune responses in cattle injected with a *Brucella abortus* soluble antigen. *Vet Microbiol*. 1991; 29(1):27–48. [PubMed: 1835213]
- Ebel ED, Williams MS, Tomlinson SM. Estimating herd prevalence of bovine brucellosis in 46 USA states using slaughter surveillance. *Prev Vet Med*. 2008; 85(3–4):295–316. [PubMed: 18359525]
- Edmonds MD, Cloeckert A, Elzer PH. *Brucella* species lacking the major outer membrane protein Omp25 are attenuated in mice and protect against *Brucella melitensis* and *Brucella ovis*. *Vet Microbiol*. 2002a; 88(3):205–221. [PubMed: 12151196]
- Edmonds MD, Cloeckert A, Hagius SD, Samartino LE, Fulton WT, Walker JV, Enright FM, Booth NJ, Elzer PH. Pathogenicity and protective activity in pregnant goats of a *Brucella melitensis* Δ omp25 deletion mutant. *Res Vet Sci*. 2002b; 72(3):235–239. [PubMed: 12076120]
- Eker A, Uzunca I, Tansel O, Birtane M. A patient with brucellar cervical spondylodiscitis complicated by epidural abscess. *J Clin Neurosci*. 2011; 18(3):428–430. [PubMed: 21239174]
- el Idrissi AH, Benkirane A, el Maadoudi M, Bouslikhane M, Berrada J, Zerouali A. Comparison of the efficacy of *Brucella abortus* strain RB51 and *Brucella melitensis* Rev. 1 live vaccines against experimental infection with *Brucella melitensis* in pregnant ewes. *Rev Sci Tech*. 2001; 20(3):741–747. [PubMed: 11732416]

- Elberg SS, Faunce KJ Jr. Immunization against *Brucella* infection. VI. Immunity conferred on goats by a nondependent mutant from a streptomycin-dependent mutant strain of *Brucella melitensis*. *J Bacteriol.* 1957; 73(2):211–217. [PubMed: 13416171]
- Elzer PH, Edmonds MD, Hagius SD, Walker JV, Gilsdorf MJ, Davis DS. Safety of *Brucella abortus* strain RB51 in Bison. *J Wildl Dis.* 1998; 34(4):825–829. [PubMed: 9813857]
- Entessar F, Ardalan A, Ebadi A, Jones LM. Effect of living Rev. 1 vaccine in producing long-term immunity against *Brucella melitensis* infection in sheep in Iran. *J Comp Pathol.* 1967; 77(4):367–376. [PubMed: 5625649]
- Eschenbrenner M, Horn TA, Wagner MA, Mujer CV, Miller-Scandle TL, DeVecchio VG. Comparative proteome analysis of laboratory grown *Brucella abortus* 2308 and *Brucella melitensis* 16M. *J Proteome Res.* 2006; 5(7):1731–1740. [PubMed: 16823981]
- Fensterbank R, Pardon P, Marly J. Efficacy of *Brucella melitensis* Rev. 1 vaccine against *Brucella ovis* infection in rams. *Ann Rech Vet.* 1982; 13(2):185–190. [PubMed: 7168540]
- Ferguson GP, Datta A, Baumgartner J, Roop RM 2nd, Carlson RW, Walker GC. Similarity to peroxisomal-membrane protein family reveals that *Sinorhizobium* and *Brucella* BacA affect lipid-A fatty acids. *Proc Natl Acad Sci USA.* 2004; 101(14):5012–5017. [PubMed: 15044696]
- Ferrero MC, Fossati CA, Baldi PC. Smooth *Brucella* strains invade and replicate in human lung epithelial cells without inducing cell death. *Microbes Infect.* 2009; 11(4):476–483. [PubMed: 19397873]
- Fiorentino MA, Campos E, Cravero S, Arese A, Paolicchi F, Campero C, Rossetti O. Protection levels in vaccinated heifers with experimental vaccines *Brucella abortus* M1-*luc* and INTA 2. *Vet Microbiol.* 2008; 132(3–4):302–311. [PubMed: 18565697]
- Fosgate GT, Adesiyun AA, Hird DW, Johnson WO, Hietala SK, Schurig GG, Ryan J, Diptee MD. Evaluation of brucellosis RB51 vaccine for domestic water buffalo (*Bubalus bubalis*) in Trinidad. *Prev Vet Med.* 2003; 58(3–4):211–225. [PubMed: 12706059]
- Foulongne V, Walravens K, Bourg G, Boschirolu ML, Godfroid J, Ramuz M, O'Callaghan D. Aromatic compound-dependent *Brucella suis* is attenuated in both cultured cells and mouse models. *Infect Immun.* 2001; 69(1):547–550. [PubMed: 11119550]
- Franco MP, Mulder M, Gilman RH, Smits HL. Human brucellosis. *Lancet Infect Dis.* 2007; 7(12):775–786. [PubMed: 18045560]
- Galindo RC, Muñoz PM, de Miguel MJ, Marin CM, Labairu J, Revilla M, Blasco JM, Gortazar C, de la Fuente J. Gene expression changes in spleens of the wildlife reservoir species, Eurasian wild boar (*Sus scrofa*), naturally infected with *Brucella suis* biovar 2. *J Genet Genomics.* 2010; 37(11):725–736. [PubMed: 21115167]
- García-Carrillo C. Comparison of *B. melitensis* Rev. 1 and *B. abortus* strain 19 as a vaccine against brucellosis in cattle. *Zentralbl Veterinarmed B.* 1980; 27(2):131–138. [PubMed: 6781179]
- González D, Grilló MJ, De Miguel MJ, Ali T, Arce-Gorvel V, Delrue RM, Conde-Alvarez R, Muñoz P, López-Goñi I, Iriarte M, Marín CM, Weintraub A, Widmalm G, Zygmunt M, Letesson JJ, Gorvel JP, Blasco JM, Moriyón I. Brucellosis vaccines: assessment of *Brucella melitensis* lipopolysaccharide rough mutants defective in core and O-polysaccharide synthesis and export. *PLoS ONE.* 2008; 3(7):e2760. [PubMed: 18648644]
- Graves RR. The story of John M. Buck's and Matilda's contribution to the cattle industry. *J Am Vet Med Assoc.* 1943; 102:193–195.
- Gulsun S, Aslan S, Satıcı O, Gul T. Brucellosis in pregnancy. *Trop Doct.* 2011; 41(2):82–84. [PubMed: 21378061]
- Haag AF, Myka KK, Arnold MF, Caro-Hernández P, Ferguson GP. Importance of lipopolysaccharide and cyclic β -1,2-glucans in *Brucella*-mammalian infections. *Int J Microbiol.* 2010; 2010:1–12.
- Hall WH. Modern chemotherapy for brucellosis in humans. *Rev Infect Dis.* 1990; 12(6):1060–1099. [PubMed: 2267485]
- Halling SM, Peterson-Burch BD, Bricker BJ, Zuerner RL, Qing Z, Li LL, Kapur V, Alt DP, Olsen SC. Completion of the genome sequence of *Brucella abortus* and comparison to the highly similar genomes of *Brucella melitensis* and *Brucella suis*. *J Bacteriol.* 2005; 187 (8):2715–2726. [PubMed: 15805518]

- Herrera E, Rivera A, Palomares EG, Hernández-Castro R, Díaz-Aparicio E. Isolation of *Brucella melitensis* from a RB51-vaccinated seronegative goat. *Trop Anim Health Prod.* 2011; 43(6):1069–1070. [PubMed: 21455694]
- Hofer E, Revilla-Fernández S, Al Dahouk S, Riehm JM, Nöckler K, Zygmunt MS, Cloeckaert A, Tomaso H, Scholz HC. A potential novel *Brucella* species isolated from mandibular lymph nodes of red foxes in Austria. *Vet Microbiol.* 2012; 155(1):93–99. [PubMed: 21908110]
- Jelastopulu E, Bikas C, Petropoulos C, Leotsinidis M. Incidence of human brucellosis in a rural area in Western Greece after the implementation of a vaccination programme against animal brucellosis. *BMC Public Health.* 2008; 8(1):241–245. [PubMed: 18637172]
- Jiménez de Bagüés MP, Barberán M, Marín CM, Blasco JM. The *Brucella abortus* RB51 vaccine does not confer protection against *Brucella ovis* in rams. *Vaccine.* 1995; 13(3):301–304. [PubMed: 7631517]
- Jiménez de Bagüés MP, Marín CM, Barberán M, Blasco JM. Responses of ewes to *B. melitensis* Rev1 vaccine administered by subcutaneous or conjunctival routes at different stages of pregnancy. *Ann Rech Vet.* 1989; 20(2):205–213. [PubMed: 2751232]
- Kaushik P, Singh DK, Kumar SV, Tiwari AK, Shukla G, Dayal S, Chaudhuri P. Protection of mice against *Brucella abortus* 544 challenge by vaccination with recombinant OMP28 adjuvanted with CpG oligonucleotides. *Vet Res Commun.* 2010; 34(2):119–132. [PubMed: 20013309]
- Keller R, Hilton TD, Rios H, Boedeker EC, Kaper JB. Development of a live oral attaching and effacing *Escherichia coli* vaccine candidate using *Vibrio cholerae* CVD 103-HgR as antigen vector. *Microb Pathog.* 2010; 48(1):1–8. [PubMed: 19878715]
- Kim S, Lee DS, Watanabe K, Furuoka H, Suzuki H, Watarai M. Interferon- γ promotes abortion due to *Brucella* infection in pregnant mice. *BMC Microbiol.* 2005; 5(1):1–11. [PubMed: 15649330]
- Kojouri GA, Gholami M. Post vaccination follow-up of *Brucella melitensis* in blood stream of sheep by PCR assay. *Comp Clin Pathol.* 2009; 18(4):439–442.
- Kolar, J. Assignment Report on WHO Project MOG BLG 001, SEA/Vaccine/89. 1977. *Brucella* vaccines production in Mongolia. World Health Organization; p. 40
- Kreeger TJ, Cook WE, Edwards WH, Elzer PH, Olsen SC. *Brucella abortus* strain RB51 vaccination in elk. II. Failure of high dosage to prevent abortion. *J Wildl Dis.* 2002; 38(1):27–31. [PubMed: 11838225]
- Kreeger TJ, Miller MW, Wild MA, Elzer PH, Olsen SC. Safety and efficacy of *Brucella abortus* strain RB51 vaccine in captive pregnant elk. *J Wildl Dis.* 2000; 36(3):477–483. [PubMed: 10941732]
- Kurar E, Splitter GA. Nucleic acid vaccination of *Brucella abortus* ribosomal L7/L12 gene elicits immune response. *Vaccine.* 1997; 15 (17–18):1851–1857. [PubMed: 9413093]
- Lavigne JP, Patey G, Sangari FJ, Bourg G, Ramuz M, O'Callaghan D, Michaux-Charachon S. Identification of a new virulence factor, BvfA, in *Brucella suis*. *Infect Immun.* 2005; 73(9):5524–5529. [PubMed: 16113268]
- Levine MM, Ferreccio C, Abrego P, Martin OS, Ortiz E, Cryz S. Duration of efficacy of Ty21a, attenuated *Salmonella typhi* live oral vaccine. *Vaccine.* 1999; 17(Suppl 2):S22–S27. [PubMed: 10506405]
- Li YK. A study on one strain of *Brucella canis* isolated from a cow at the first time. *Zhonghua Liu Xing Bing Xue Za Zhi.* 1988; 9(6):342–344. [PubMed: 3245961]
- Loisel-Meyer S, Jiménez de Bagüés MP, Bassères E, Dornand J, Köhler S, Liautard JP, Jubier-Maurin V. Requirement of *norD* for *Brucella suis* virulence in a murine model of *in vitro* and *in vivo* infection. *Infect Immun.* 2006; 74(3):1973–1976. [PubMed: 16495577]
- Lord VR, Schurig GG, Cherwonogrodzky JW, Marcano MJ, Melendez GE. Field study of vaccination of cattle with *Brucella abortus* strains RB51 and 19 under high and low disease prevalence. *Am J Vet Res.* 1998; 59(8):1016–1020. [PubMed: 9706206]
- Manthei CA. Summary of controlled research with strain 19. *Proc Annu Meet US Livest Sanit Assoc.* 1959; 63:91–97.
- Marín CM, Moreno E, Moriyón I, Díaz R, Blasco JM. Performance of competitive and indirect enzyme-linked immunosorbent assays, gel immunoprecipitation with native hapten polysaccharide, and standard serological tests in diagnosis of sheep brucellosis. *Clin Diagn Lab Immunol.* 1999; 6(2):269–272. [PubMed: 10066666]

- Martínez de Tejada G, Pizarro-Cerdá J, Moreno E, Moriyón I. The outer membranes of *Brucella* spp. are resistant to bactericidal cationic peptides. *Infect Immun*. 1995; 63(8):3054–3061. [PubMed: 7622230]
- Memish Z, Mah MW, Al Mahmoud S, Al Shaalan M, Khan MY. *Brucella* bacteraemia: clinical and laboratory observations in 160 patients. *J Infect*. 2000; 40(1):59–63. [PubMed: 10762113]
- Minas A, Minas M, Stournara A, Tselepidis S. The “effects” of Rev-1 vaccination of sheep and goats on human brucellosis in Greece. *Prev Vet Med*. 2004; 64(1):41–47. [PubMed: 15219968]
- Mingle CK, Manthei CA, Jasmin AM. The stability of reduced virulence exhibited by *Brucella abortus* strain 19. *J Am Vet Med Assoc*. 1941; 99:203–204.
- Moreno, E.; Moriyón, I. Genus *Brucella*. In: Dworkin, editor. *The procaryotes: an evolving microbiological resource for the microbiological community*. Springer; New York, NY: 2001.
- Moriyón I, Grilló MJ, Monreal D, González D, Marín C, López-Goñi I, Mainar-Jaime RC, Moreno E, Blasco JM. Rough vaccines in animal brucellosis: structural and genetic basis and present status. *Vet Res*. 2004; 35(1):1–38. [PubMed: 15099501]
- Mukherjee F, Jain J, Grilló MJ, Blasco JM, Nair M. Evaluation of *Brucella abortus* S19 vaccine strains by bacteriological tests, molecular analysis of *ery* loci and virulence in BALB/c mice. *Biologicals*. 2005; 33(3):153–160. [PubMed: 16081301]
- Muñoz PM, de Miguel MJ, Grilló MJ, Marín CM, Barberán M, Blasco JM. Immunopathological responses and kinetics of *Brucella melitensis* Rev 1 infection after subcutaneous or conjunctival vaccination in rams. *Vaccine*. 2008; 26(21):2562–2569. [PubMed: 18423950]
- Muñoz-Montesino C, Andrews E, Rivers R, González-Smith A, Moraga-Cid G, Folch H, Céspedes S, Oñate AA. Intraspleen delivery of a DNA vaccine coding for superoxide dismutase (SOD) of *Brucella abortus* induces SOD-specific CD4⁺ and CD8⁺ T cells. *Infect Immun*. 2004; 72(4):2081–2087. [PubMed: 15039330]
- O’Callaghan D, Maskell D, Liew FY, Easmon CS, Dougan G. Characterization of aromatic- and purine-dependent *Salmonella typhimurium*: attention, persistence, and ability to induce protective immunity in BALB/c mice. *Infect Immun*. 1988; 56(2):419–423. [PubMed: 3276625]
- Olsen SC. Brucellosis in the United States: role and significance of wildlife reservoirs. *Vaccine*. 2010; 28(Suppl 5):F73–F76. [PubMed: 20362627]
- Olsen SC, Boyle SM, Schurig GG, Sriranganathan NN. Immune responses and protection against experimental challenge after vaccination of bison with *Brucella abortus* strain RB51 or RB51 overexpressing superoxide dismutase and glycosyltransferase genes. *Clin Vaccine Immunol*. 2009; 16(4):535–540. [PubMed: 19176693]
- Olsen SC, Fach SJ, Palmer MV, Sacco RE, Stoffregen WC, Waters WR. Immune responses of elk to initial and booster vaccinations with *Brucella abortus* strain RB51 or 19. *Clin Vaccine Immunol*. 2006; 13 (10):1098–1103. [PubMed: 17028213]
- Olsen SC, Hennager SG. Immune responses and protection against experimental *Brucella suis* biovar 1 challenge in nonvaccinated or *B. abortus* strain RB51-vaccinated cattle. *Clin Vaccine Immunol*. 2010; 17(12):1891–1895. [PubMed: 20943881]
- Olsen SC, Holland SD. Safety of revaccination of pregnant bison with *Brucella abortus* strain RB51. *J Wildl Dis*. 2003; 39(4):824–829. [PubMed: 14733277]
- Olsen SC, Jensen AE, Stoffregen WC, Palmer MV. Efficacy of calfhood vaccination with *Brucella abortus* strain RB51 in protecting bison against brucellosis. *Res Vet Sci*. 2003; 74(1):17–22. [PubMed: 12507562]
- Oñate AA, Donoso G, Moraga-Cid G, Folch H, Céspedes S, Andrews E. An RNA vaccine based on recombinant Semliki Forest virus particles expressing the Cu, Zn superoxide dismutase protein of *Brucella abortus* induces protective immunity in BALB/c mice. *Infect Immun*. 2005; 73(6):3294–3300. [PubMed: 15908354]
- Osorio M, Wu Y, Singh S, Merkel TJ, Bhattacharyya S, Blake MS, Kopecko DJ. Anthrax protective antigen delivered by *Salmonella enterica* serovar Typhi Ty21a protects mice from a lethal anthrax spore challenge. *Infect Immun*. 2009; 77(4):1475–1482. [PubMed: 19179420]
- Palmer MV, Cheville NF, Jensen AE. Experimental infection of pregnant cattle with the vaccine candidate *Brucella abortus* strain RB51: pathologic, bacteriologic, and serologic findings. *Vet Pathol*. 1996a; 33(6):682–691. [PubMed: 8952027]

- Palmer MV, Olsen SC, Gilsdorf MJ, Philo LM, Clarke PR, Cheville NF. Abortion and placentitis in pregnant bison (*Bison bison*) induced by the vaccine candidate, *Brucella abortus* strain RB51. *Am J Vet Res*. 1996b; 57(11):1604–1607. [PubMed: 8915438]
- Pappas G, Akritidis N, Bosilkovski M, Tsianos E. Brucellosis. *N Engl J Med*. 2005; 352(22):2325–2336. [PubMed: 15930423]
- Pappas G, Panagopoulou P, Christou L, Akritidis N. *Brucella* as a biological weapon. *Cell Mol Life Sci*. 2006a; 63(19–20):2229–2236. [PubMed: 16964579]
- Pappas G, Papadimitriou P, Akritidis N, Christou L, Tsianos EV. The new global map of human brucellosis. *Lancet Infect Dis*. 2006b; 6(2):91–99. [PubMed: 16439329]
- Pasquevich KA, Estein SM, García Samartino C, Zwerdling A, Coria LM, Barrionuevo P, Fossati CA, Giambartolomei GH, Cassataro J. Immunization with recombinant *Brucella* species outer membrane protein Omp16 or Omp19 in adjuvant induces specific CD4⁺ and CD8⁺ T cells as well as systemic and oral protection against *Brucella abortus* infection. *Infect Immun*. 2009; 77(1):436–445. [PubMed: 18981242]
- Petrovska L, Hewinson RG, Dougan G, Maskell DJ, Woodward MJ. *Brucella melitensis* 16M: characterisation of the *galE* gene and mouse immunisation studies with a *galE* deficient mutant. *Vet Microbiol*. 1999; 65(1):21–36. [PubMed: 10068125]
- Phillips RW, Elzer PH, Robertson GT, Hagius SD, Walker JV, Fatemi MB, Enright FM, Roop RM 2nd. A *Brucella melitensis* high-temperature-requirement A (*htrA*) deletion mutant is attenuated in goats and protects against abortion. *Res Vet Sci*. 1997; 63(2):165–167. [PubMed: 9429252]
- Pishva E, Salehi M. First report of isolation of *Brucella melitensis*, vaccine strain Rev.1 as a source of cattle infection in Iran. *J Sci Islam Repub Iran*. 2008; 19:19–23.
- Poester FP, Goncalves VS, Paixao TA, Santo RL, Olsen SC, Schurig GG, Lage AP. Efficacy of strain RB51 vaccine in heifers against experimental brucellosis. *Vaccine*. 2006; 24:5327–5334. [PubMed: 16713034]
- Pontes DS, Dorella FA, Ribeiro LA, Miyoshi A, Le Loir Y, Gruss A, Oliveira SC, Langella P, Azevedo V. Induction of partial protection in mice after oral administration of *Lactococcus lactis* producing *Brucella abortus* L7/L12 antigen. *J Drug Target*. 2003; 11(8–10):489–493. [PubMed: 15203917]
- Pourbagher MA, Pourbagher A, Savas L, Turunc T, Demiroglu YZ, Erol I, Yalcintas D. Clinical pattern and abdominal sonographic findings in 251 cases of brucellosis in southern Turkey. *AJR Am J Roentgenol*. 2006; 187(2):W191–4. [PubMed: 16861510]
- Pugh GWJ Jr, Tabatabai LB, Bricker BJ, Mayfield JE, Phillips M, Zehr ES, Belzer CA. Immunogenicity of *Brucella*-extracted and recombinant protein vaccines in CD-1 and BALB/c mice. *Am J Vet Res*. 1990; 51(9):1413–1420. [PubMed: 2118744]
- Radwan AI, Bekairi SI, Mukayel AA, al-Bokmy AM, Prasad PV, Azar FN, Coloyan ER. Control of *Brucella melitensis* infection in a large camel herd in Saudi Arabia using antibiotherapy and vaccination with Rev. 1 vaccine. *Rev Sci Tech*. 1995; 14(3):719–732. [PubMed: 8593404]
- Rafiei A, Ardestani SK, Kariminia A, Keyhani A, Mohraz M, Amirkhani A. Dominant Th1 cytokine production in early onset of human brucellosis followed by switching towards Th2 along prolongation of disease. *J Infect*. 2006; 53(5):315–324. [PubMed: 16488475]
- Rajasekaran P, Surendran N, Seleem MN, Sriranganathan N, Schurig GG, Boyle SM. Over-expression of homologous antigens in a leucine auxotroph of *Brucella abortus* strain RB51 protects mice against a virulent *B. suis* challenge. *Vaccine*. 2011; 29(17):3106–3110. [PubMed: 21376799]
- Rajashekara G, Krepps M, Eskra L, Mathison A, Montgomery A, Ishii Y, Splitter G. Unraveling *Brucella* genomics and pathogenesis in immunocompromised IRF-1^{-/-} mice. *Am J Reprod Immunol*. 2005; 54(6):358–368. [PubMed: 16305661]
- Robertson GT, Elzer PH, Roop RM 2nd. *In vitro* and *in vivo* phenotypes resulting from deletion of the high temperature requirement A (*htrA*) gene from the bovine vaccine strain *Brucella abortus* S19. *Vet Microbiol*. 1996; 49(3–4):197–207. [PubMed: 8734637]
- Roop RM 2nd, Jeffers G, Bagchi T, Walker J, Enright FM, Schurig GG. Experimental infection of goat fetuses *in utero* with a stable, rough mutant of *Brucella abortus*. *Res Vet Sci*. 1991; 51(2):123–127. [PubMed: 1788475]

- Roop RM 2nd, Phillips RW, Hagius S, Walker JV, Booth NJ, Fulton WT, Edmonds MD, Elzer PH. Re-examination of the role of the *Brucella melitensis* HtrA stress response protease in virulence in pregnant goats. *Vet Microbiol.* 2001; 82(1):91–95. [PubMed: 11423199]
- Roth F, Zinsstag J, Orkhon D, Chimed-Ochir G, Hutton G, Cosivi O, Carrin G, Otte J. Human health benefits from livestock vaccination for brucellosis: case study. *Bull World Health Organ.* 2003; 81 (12):867–876. [PubMed: 14997239]
- Sangari FJ, Agüero J. Identification of *Brucella abortus* B19 vaccine strain by the detection of DNA polymorphism at the *ery* locus. *Vaccine.* 1994; 12(5):435–438. [PubMed: 7912870]
- Sangari FJ, García-Lobo JM, Agüero J. The *Brucella abortus* vaccine strain B19 carries a deletion in the erythritol catabolic genes. *FEMS Microbiol Lett.* 1994; 121(3):337–342. [PubMed: 7926690]
- Schlalitz-Loutsevitch NE, Whatmore AM, Quance CR, Koylass MS, Cummins LB, Dick EJ Jr, Snider CL, Cappelli D, Ebersole JL, Nathanielsz PW, Hubbard GB. A novel *Brucella* isolate in association with two cases of stillbirth in non-human primates - first report. *J Med Primatol.* 2009; 38(1):70–73. [PubMed: 19187435]
- Schurig GG, Roop RM 2nd, Bagchi T, Boyle S, Buhrman D, Sriranganathan N. Biological properties of RB51; a stable rough strain of *Brucella abortus*. *Vet Microbiol.* 1991; 28(2):171–188. [PubMed: 1908158]
- SCOFCAH. Portugal: Results of the implementation of the sheep and goat brucellosis eradication programme 2010 Standing Committee on the Food Chain and Animal Health (SCOFCAH); Brussels . 2011. http://ec.europa.eu/food/committees/regulatory/scfcah/animal_health/presentations/0708092011_brucellosis_portugal.pdf
- Scurlock BM, Edwards WH. Status of brucellosis in free-ranging elk and bison in Wyoming. *J Wildl Dis.* 2010; 46(2):442–449. [PubMed: 20688637]
- Shi D, Song Y, Li YJ. Progress on *Lactococcus lactis* expressing heterologous antigens as live mucosal vaccines. *Wei Sheng Wu Xue Bao.* 2006; 46(4):680–683. [PubMed: 17037080]
- Silva TM, Costa EA, Paixão TA, Tsois RM, Santos RL. Laboratory animal models for brucellosis research. *J Biomed Biotechnol.* 2011a; 2011:518323. [PubMed: 21403904]
- Silva TM, Paixão TA, Costa EA, Xavier MN, Sá JC, Moustakas VS, den Hartigh AB, Carvalho Neta AV, Oliveira SC, Tsois R, Santos RL. Putative ATP-binding cassette transporter is essential for *Brucella ovis* pathogenesis in mice. *Infect Immun.* 2011b; 79(4):1706–1717. [PubMed: 21300772]
- Smith LD, Ficht TA. Pathogenesis of *Brucella*. *Crit Rev Microbiol.* 1990; 17(3):209–230. [PubMed: 2154232]
- Smither SJ, Perkins SD, Davies C, Stagg AJ, Nelson M, Atkins HS. Development and characterization of mouse models of infection with aerosolized *Brucella melitensis* and *Brucella suis*. *Clin Vaccine Immunol.* 2009; 16(5):779–783. [PubMed: 19321692]
- Spink WW, Hall JW 3rd, Finstad J, Mallet E. Immunization with viable *Brucella* organisms. Results of a safety test in humans. *Bull World Health Organ.* 1962; 26:409–419. [PubMed: 13915813]
- Stabel TJ, Mayfield JE, Morfitt DC, Wannemuehler MJ. Oral immunization of mice and swine with an attenuated *Salmonella choleraesuis* [delta *cya*-12 delta(*crp*-*cdt*)19] mutant containing a recombinant plasmid. *Infect Immun.* 1993; 61(2):610–618. [PubMed: 8423090]
- Stabel TJ, Mayfield JE, Tabatabai LB, Wannemuehler MJ. Oral immunization of mice with attenuated *Salmonella typhimurium* containing a recombinant plasmid which codes for production of a 31-kilodalton protein of *Brucella abortus*. *Infect Immun.* 1990; 58(7):2048–2055. [PubMed: 2114357]
- Stabel TJ, Mayfield JE, Tabatabai LB, Wannemuehler MJ. Swine immunity to an attenuated *Salmonella typhimurium* mutant containing a recombinant plasmid which codes for production of a 31-kilodalton protein of *Brucella abortus*. *Infect Immun.* 1991; 59(9):2941–2947. [PubMed: 1908827]
- Stevens MG, Hennager SG, Olsen SC, Cheville NF. Serologic responses in diagnostic tests for brucellosis in cattle vaccinated with *Brucella abortus* 19 or RB51. *J Clin Microbiol.* 1994; 32(4):1065–1066. [PubMed: 8027313]
- Stevens MG, Olsen SC. Antibody responses to *Brucella abortus* 2308 in cattle vaccinated with *B. abortus* RB51. *Infect Immun.* 1996; 64(3):1030–1034. [PubMed: 8641754]

- Stevens MG, Olsen SC, Cheville NF. Comparative analysis of immune responses in cattle vaccinated with *Brucella abortus* strain 19 or strain RB51. *Vet Immunol Immunopathol.* 1995a; 44(3–4): 223–235. [PubMed: 7747403]
- Stevens MG, Olsen SC, Pugh GW Jr, Brees D. Comparison of immune responses and resistance to brucellosis in mice vaccinated with *Brucella abortus* 19 or RB51. *Infect Immun.* 1995b; 63(1): 264–270. [PubMed: 7806364]
- Taylor AW, McDiarmid A. The stability of the avirulent characters of *Brucella abortus*, strain 19 and strain 45/20 in lactating and pregnant cows. *Vet Rec.* 1949; 61:317–318.
- Teske SS, Huang Y, Tamrakar SB, Bartrand TA, Weir MH, Haas CN. Animal and human dose-response models for *Brucella* species. *Risk Anal.* 2011; 31(10):1576–1596. [PubMed: 21449960]
- Thorne, ET. Cheyenne, Wyoming Game and Fish Dept. for Greater Yellowstone Interagency Brucellosis Committee. 1997. Brucellosis, bison, elk, and cattle in the Greater Yellowstone area: defining the problem, exploring solutions.
- Tibor A, Jacques I, Guilloteau L, Verger JM, Grayon M, Wansard V, Letesson JJ. Effect of P39 gene deletion in live *Brucella* vaccine strains on residual virulence and protective activity in mice. *Infect Immun.* 1998; 66(11):5561–5564. [PubMed: 9784574]
- Trant CG, Lacerda TL, Carvalho NB, Azevedo V, Rosinha GM, Salcedo SP, Gorvel JP, Oliveira SC. The *Brucella abortus* phosphoglycerate kinase mutant is highly attenuated and induces protection superior to that of vaccine strain 19 in immunocompromised and immunocompetent mice. *Infect Immun.* 2010; 78(5):2283–2291. [PubMed: 20194591]
- Treanor JJ, Johnson JS, Wallen RL, Cilles S, Crowley PH, Cox JJ, Maehr DS, White PJ, Plumb GE. Vaccination strategies for managing brucellosis in Yellowstone bison. *Vaccine.* 2010; 28(Suppl 5):F64–F72. [PubMed: 20362620]
- Ugalde JE, Comerci DJ, Leguizamón MS, Ugalde RA. Evaluation of *Brucella abortus* phosphoglucomutase (*pgm*) mutant as a new live rough-phenotype vaccine. *Infect Immun.* 2003; 71(11):6264–6269. [PubMed: 14573645]
- Valderas MW, Barrow WW. Establishment of a method for evaluating intracellular antibiotic efficacy in *Brucella abortus*-infected Mono Mac 6 monocytes. *J Antimicrob Chemother.* 2008; 61(1):128–134. [PubMed: 18024491]
- Van Campen H, Rhyhan J. The role of wildlife in diseases of cattle. *Vet Clin North Am Food Anim Pract.* 2010; 26(1):147–161. [PubMed: 20117548]
- Velikovskiy CA, Cassataro J, Giambartolomei GH, Goldbaum FA, Estein S, Bowden RA, Bruno L, Fossati CA, Spitz M. A DNA vaccine encoding lumazine synthase from *Brucella abortus* induces protective immunity in BALB/c mice. *Infect Immun.* 2002; 70(5):2507–2511. [PubMed: 11953389]
- Vemulapalli R, Contreras A, Sanakkayala N, Sriranganathan N, Boyle SM, Schurig GG. Enhanced efficacy of recombinant *Brucella abortus* RB51 vaccines against *B. melitensis* infection in mice. *Vet Microbiol.* 2004; 102(3–4):237–245. [PubMed: 15327798]
- Verger JM, Grayon M, Zundel E, Lechopier P, Olivier-Bernardin V. Comparison of the efficacy of *Brucella suis* strain 2 and *Brucella melitensis* Rev. 1 live vaccines against a *Brucella melitensis* experimental infection in pregnant ewes. *Vaccine.* 1995; 13(2):191–196. [PubMed: 7625115]
- Walker GC, LeVier K, Phillips RW, Grippe VK, Roop RM 2nd. Similar requirements of a plant symbiont and a mammalian pathogen for prolonged intracellular survival. *Science.* 2000; 287:2492–2493. [PubMed: 10741969]
- Wang Y, Bai Y, Qu Q, Xu J, Chen Y, Zhong Z, Qiu Y, Wang T, Du X, Wang Z, Yu S, Fu S, Yuan J, Zhen Q, Yu Y, Chen Z, Huang L. The 16MΔvjbR as an ideal live attenuated vaccine candidate for differentiation between *Brucella* vaccination and infection. *Vet Microbiol.* 2011; 151(3–4): 354–362. [PubMed: 21530111]
- Ward D, Jackson R, Karomatullo H, Khakimov T, Kurbonov K, Amirbekov M, Stack J, El-Idrissi A, Heuer C. Brucellosis control in Tajikistan using Rev 1 vaccine: change in seroprevalence in small ruminants from 2004 to 2009. *Vet Rec.* 2011
- Whatmore AM. Current understanding of the genetic diversity of *Brucella*, an expanding genus of zoonotic pathogens. *Infect Genet Evol.* 2009; 9(6):1168–1184. [PubMed: 19628055]

- Winter AJ, Rowe GE, Duncan JR, Eis MJ, Widom J, Ganem B, Morein B. Effectiveness of natural and synthetic complexes of porin and O polysaccharide as vaccines against *Brucella abortus* in mice. *Infect Immun*. 1988; 56(11):2808–2817. [PubMed: 2844673]
- Wise RI. Brucellosis in the United States. Past, present, and future. *JAMA*. 1980; 244(20):2318–2322. [PubMed: 7001058]
- Wyckoff JH 3rd, Howland JL, Scott CM, Smith RA, Confer AW. Recombinant bovine interleukin 2 enhances immunity and protection induced by *Brucella abortus* vaccines in cattle. *Vet Microbiol*. 2005; 111(1–2):77–87. [PubMed: 16242273]
- Xavier MN, Paixão TA, Poester FP, Lage AP, Santos RL. Pathological, immunohistochemical and bacteriological study of tissues and milk of cows and fetuses experimentally infected with *Brucella abortus*. *J Comp Pathol*. 2009; 140(2–3):149–157. [PubMed: 19111839]
- Xin X. Orally administrable brucellosis vaccine: *Brucella suis* strain 2 vaccine. *Vaccine*. 1986; 4(4): 212–216. [PubMed: 3541425]
- Yang X, Becker T, Walters N, Pascual DW. Deletion of *znuA* virulence factor attenuates *Brucella abortus* and confers protection against wild-type challenge. *Infect Immun*. 2006; 74(7):3874–3879. [PubMed: 16790759]
- Yang X, Hinnebusch BJ, Trunkle T, Bosio CM, Suo Z, Tighe M, Harmsen A, Becker T, Crist K, Walters N, Avci R, Pascual DW. Oral vaccination with *salmonella* simultaneously expressing *Yersinia pestis* F1 and V antigens protects against bubonic and pneumonic plague. *J Immunol*. 2007; 178(2):1059–1067. [PubMed: 17202369]
- Yang X, Hudson M, Walters N, Bargatze RF, Pascual DW. Selection of protective epitopes for *Brucella melitensis* by DNA vaccination. *Infect Immun*. 2005; 73(11):7297–7303. [PubMed: 16239526]
- Yang X, Thornburg T, Walters N, Pascual DW. $\Delta znuA\Delta apuE$ *Brucella abortus* 2308 mutant as a live vaccine candidate. *Vaccine*. 2010; 28(4):1069–1074. [PubMed: 19914192]
- Yang Y, Yin J, Guo D, Lang X, Wang X. Immunization of mice with recombinant S-adenosyl-L-homocysteine hydrolase protein confers protection against *Brucella melitensis* infection. *FEMS Immunol Med Microbiol*. 2011; 61(2):159–167. [PubMed: 21166726]
- Young, EJ. Clinical manifestations of human brucellosis. In: Young, EJ.; Corbel, MJ., editors. *Brucellosis: clinical and laboratory aspects*. CRC Press, Inc; Boca Raton, Fla: 1989. p. 97-126.
- Yu DH, Hu XD, Cai H, Li M. A combined DNA vaccine encoding BCSP31, SOD, and L7/L12 confers high protection against *Brucella abortus* 2308 by inducing specific CTL responses. *DNA Cell Biol*. 2007; 26(6):435–443. [PubMed: 17570767]
- Zhan Y, Cheers C. Endogenous gamma interferon mediates resistance to *Brucella abortus* infection. *Infect Immun*. 1993; 61(11):4899–4901. [PubMed: 8406893]
- Zhao Z, Li M, Luo D, Xing L, Wu S, Duan Y, Yang P, Wang X. Protection of mice from *Brucella* infection by immunization with attenuated *Salmonella enterica* serovar typhimurium expressing A L7/L12 and BLS fusion antigen of *Brucella*. *Vaccine*. 2009; 27(38):5214–5219. [PubMed: 19596411]
- Zinsstag J, Roth F, Orkhon D, Chimed-Ochir G, Nansalma M, Kolar J, Vounatsou P. A model of animal-human brucellosis transmission in Mongolia. *Prev Vet Med*. 2005; 69(1–2):77–95. [PubMed: 15899298]
- Zowghi E, Ebadi A. Naturally occurring *Brucella melitensis* infection in cattle in Iran. *Rev Sci Tech Off Int Epiz*. 1985; 4:811–814.

Figure 1.

The transmission chain of *Brucella* spp. among wildlife, livestock, and human. Livestock acquires the *Brucella* diseases from the natural reservoirs, such as bison, elk, and deer. Subsequently, humans are infected by the sick livestock and/or its products, either via inhalation of contaminated aerosol, ingestion of foods such as unpasteurized milk and cheese, or direct contact with the sick livestock and its contaminated products.

Table 1

Live vaccine immunization regimens and protective efficacies

Live vaccine strains	Animals	Immunization dose/ route ¹	Challenge strain ² / dose/route ¹	Efficacy ³ (protection against abortion)	References
<i>B. abortus</i>					
S19	heifers	10 ⁹ –10 ¹⁰ /s.c.	2308/9×10 ⁶ /i.c.	70%–91%	(Confer et al., 1985)
	heifers	10 ⁹ –10 ¹⁰ /s.c.	2308/5×10 ⁷ /i.c.	0%–20%	(Confer et al., 1985)
	heifers	10 ⁷ (×2)/s.c.	2308/9×10 ⁵ /i.c.	86%	(Wyckoff et al., 2005)
	heifers	1.0×10 ¹⁰ –1.4×10 ¹⁰ /s.c.	2308/1×10 ⁷ /i.c.	100%	(Cheville et al., 1996b)
RB51	bison	5×10 ⁸ /s.c.	2308/1×10 ⁷ /i.c.	67%	(Davis et al., 1991)
	heifers	1.0×10 ¹⁰ –1.4×10 ¹⁰ /s.c.	2308/1×10 ⁷ /i.c.	100%	(Cheville et al., 1996b)
	heifers	1.0×10 ¹⁰ –1.4×10 ¹⁰ /s.c.	2308/1×10 ⁷ /i.c.	100%	(Cheville et al., 1993)
	cattle	5×10 ⁹ /s.c.	field spp.	100%	(Lord et al., 1998)
	cows	1.5×10 ¹⁰ –1.6×10 ¹⁰ /s.c.	2308/3×10 ⁷ /i.c.	75%	(Poester et al., 2006)
	elk	10 ⁸ –10 ⁹ /i.m.,bb	2308/1×10 ⁷ /i.c.	12%–25%	(Cook et al., 2002)
	elk	10 ¹⁰ /i.m.	2308/1×10 ⁷ /i.c.	0%	(Kreeger et al., 2002)
	elk	10 ¹⁰ (×2)/i.m.	2308/1×10 ⁷ /i.c.	7%	(Kreeger et al., 2002)
<i>Δpgk</i>	BALB/c mice	10 ⁵ /i.p.	2308/1×10 ⁶ /i.p.	(log 10 units)	(Trant et al., 2010)
	C57BL/6 mice	10 ⁵ /i.p.	2308/1×10 ⁶ /i.p.	0.96	(Trant et al., 2010)
	129/Sv mice	10 ⁵ /i.p.	2308/1×10 ⁶ /i.p.	1.36	(Trant et al., 2010)
	BALB/c mice	10 ⁷ /i.p.	2308/5×10 ⁵ /i.p.	3.28	(Ugalde et al., 2003)
<i>Δpgm</i>	BALB/c mice	10 ⁸ /i.p.	2308/5×10 ⁴ /i.p.	1.9–2.3	(Yang et al., 2006)
<i>ΔznuA 2308</i>	BALB/c mice	10 ⁸ /i.p.		1.88	
<i>B. meliensis</i>					
Rev-1	goats	1.5×10 ⁹ /(uk)	640/4×10 ¹⁰ /i.m.	(protection against abortion)	(Alton, 1966)
	sheep	2×10 ⁹ /s.c.	Isfahan/6×10 ⁹ /s.c.	100%	(Entessar et al., 1967)
	goats	1.5×10 ⁹ /(uk)	field spp.	100%	(Alton, 1968)
RBM17	BALB/c mice	10 ⁸ /i.p.	16M/2×10 ⁵ /i.p.	(log 10 units)	(Adone et al., 2005)
Bm16MR _{wa}	BALB/c mice	10 ⁸ /i.p.	H38/1×10 ⁴ /i.p.	2.83	(González et al., 2008)
				3.9–4.4	

Live vaccine strains	Animals	Immunization dose/ route ¹	Challenge strain ² / dose/route ¹	Efficacy ³ (protection against abortion)	References
Bm16MR wzm	BALB/c mice	10 ⁸ /s.c.	H38/1×10 ⁴ /i.p.	4.1	(González et al., 2008)
ΔznuA 16M	BALB/c mice	3×10 ¹¹ /oral	16M/2×10 ⁴ /i.n.	3.0–4	(Clapp et al., 2011a)
	IFN-γ ^{-/-} mice	3×10 ¹¹ /oral	16M/2×10 ⁴ /i.n.	1.85	(Clapp et al., 2011a)
RWP5	goats	10 ⁹ /s.c.	16M/1×10 ⁷ /i.c.	100%	(Phillips et al., 1997)
Δomp25 16M	goats	10 ⁹ /s.c.	16M/1×10 ⁷ /i.c.	100%	(Edmonds et al., 2002b)
16MΔmucR	BALB/c mice	10 ⁹ /i.p.	16M/6×10 ⁵ /i.p.	2.79	(Arenas-Gamboa et al., 2011)
16MΔvjbR	BALB/c mice	10 ⁶ /i.p.	16M/1×10 ⁵ /i.p.	~2.4	(Wang et al., 2011)
vjbR::Tn5 16M	BALB/c mice	10 ⁵ /i.p.	16M/1×10 ⁵ /i.p.	4.98	(Arenas-Gamboa et al., 2008)
			(protection against abortion)		
<i>B. suis</i>					
S2	sheep	0.2×10 ¹⁰ –5×10 ¹⁰ /oral	<i>B. melitensis</i> 28/10 ⁷ /i.c. or 10 ⁹ /oral	82.7%	(Xin, 1986)
	goats	0.25×10 ¹⁰ –5×10 ¹⁰ /oral	<i>B. melitensis</i> 28/10 ⁷ /i.c. or 10 ⁹ /oral	82.1%	(Xin, 1986)
	sows	2×10 ¹⁰ ×10 ¹⁰ (×2)/oral	<i>B. suis</i> 12/6×10 ⁷ /oral	75.0%	(Xin, 1986)
	cows	0.25×10 ¹⁰ –5×10 ¹⁰ /oral	<i>B. abortus</i> 387/10 ⁶ –10 ⁷ /i.c.	71.4%	(Xin, 1986)

¹ Animals dosed once unless indicated with “(×2)”; s.c.: subcutaneous; i.m.: intramuscular; bb: biobullet; i.p.: intraperitoneal; i.n.: intranasal; i.c.: intraconjunctival; uk: route of immunization is unknown.

² Challenge strains: *B. abortus* 2308; *B. melitensis* 16M; or otherwise stated.

³ Efficacy in livestock is depicted as “protection against abortion” and in mice as “log10 unit” reduction in splenic colonization.

Table 2

Subunit vaccine immunization regimens and protective efficacies.

Subunit vaccines	Mice ¹	Immunization/ formula/dose/route ²	Challenge strain ³ /dose/route	Efficacy ⁴ (log10)	References
<i>B. abortus</i>					
BLS	BALB/c	DNA/100 µg (×4)/i.m.	544/10 ⁵ /i.p.	1.25–1.65	(Velikovsky et al., 2002)
InfC	BALB/c	protein/5 µg (×1)/i.p.	2308/1×10 ⁴ /i.p.	1.92	(Cespedes et al., 2000)
L7/L12	BALB/cByJ	DNA/100 µg (×1)/i.m.	2308/1×10 ⁶ /i.p.	0.47–1.26	(Kurar and Splitter, 1997)
Omp16	BALB/c	protein/10 µg (×2)/i.p.	544/4×10 ⁴ /i.p.	1.97	(Pasquevich et al., 2009)
Omp19	BALB/c	protein/10 µg (×2)/i.p.	544/4×10 ⁴ /i.p.	1.85	(Pasquevich et al., 2009)
Omp28	Swiss Albino	protein/30 µg (×2)/i.m.	544/1×10 ⁵ /i.p.	0.97	(Kaushik et al., 2010)
P39	BALB/c	protein/20 µg (×2)/i.m.	544/5×10 ⁴ /i.p.	1.21–2.48	(Al-Mairi et al., 2001)
DnaK	BALB/c	protein/30 µg (×2)/i.p.	2308/1×10 ⁴ /i.p.	0.90–0.95	(Delpino et al., 2007)
SurA	BALB/c	protein/30 µg (×2)/i.p.	2308/1×10 ⁴ /i.p.	0.97–1.45	(Delpino et al., 2007)
SodC	BALB/c	DNA/10 µg (×1)/i.s.	2308/1×10 ⁴ /i.p.	1.52	(Munoz-Montesino et al., 2004)
SodC	BALB/c	DNA/10 µg (×1)/i.m.	2308/1×10 ⁴ /i.p.	1.15	(Munoz-Montesino et al., 2004)
<i>B. melitensis</i>					
Bp26	BALB/c	DNA/300 µg (×4)/i.m.	16M/2.4×10 ⁴ /i.p.	1.16	(Yang et al., 2005)
Omp25	BALB/c	DNA/400 µg (×4)/i.m.	16M/1×10 ⁴ /i.p.	2.54	(Commander et al., 2007)
IalB	BALB/c	DNA/400 µg (×4)/i.m.	16M/1×10 ⁴ /i.p.	2.70	(Commander et al., 2007)
Omp31	BALB/c	DNA/100 µg (×4)/i.m.	H38S/1×10 ⁴ /i.v.	1.30–1.45	(Cassataro et al., 2005)
AdoHcyase	BALB/c	protein/100 µg (×2)/i.p.	16M/5×10 ⁵ /i.p.	1.13–2.13	(Yang et al., 2011)

¹ Strain of mice used.

² Vaccine composition being DNA or protein; number of doses given; and route of immunization: i.s.: intraspleen.

³ Challenge strains: *B. abortus* 2308 or 544; *B. melitensis* 16M or H38S.

⁴ Efficacy is defined as reduction of “log10 units” in splenic colonization.